Professor Jelle Barentsz

Curriculum vitae and publication record

MD PhD | Radiologist | Updated 9 November 2026

Emeritus Professor of Radiology, Radboud University Medical Center, Nijmegen
Director of Imaging, Andros Clinics, Arnhem, the Netherlands

Contact: j.barentsz@andros.nl | jelle.barentsz@radboudumc.nl
Website: mri-prostate-barentsz.nl

ORCID 0000-0003-0366-2184 | Scopus Author ID 7006484477 | ResearcherID D-3515-2009



Speaker biography

Professor Jelle Barentsz, MD, PhD, is an internationally recognised pioneer in prostate cancer imaging, Emeritus Professor of Radiology at Radboud University Medical Center and Director of Imaging at Andros Clinics in the Netherlands.

His work has helped bring MRI to the forefront of prostate cancer diagnosis. He contributed to the development and international adoption of PI-RADS and to the evidence supporting MRI before biopsy, helping clinicians target clinically significant disease while reducing unnecessary procedures. He founded the Prostate MR Reference Center in Nijmegen, combining research with specialist training and quality improvement.

His current research focuses on ferumoxtran-enhanced macrophage MRI for lymph node staging, the clinical and economic value of imaging, and the quality and accessibility of prostate MRI. Recent collaborations address artificial intelligence, MRI-based screening and standardised image-quality assessment.

Professor Barentsz is a Fellow of the International Society for Magnetic Resonance in Medicine, a member of Academia Europaea and an Honorary Member of the European Society of Urogenital Radiology (2026). His honours include the EAU Innovators in Urology Award, the Society of Abdominal Radiology Lifetime Achievement Award and a knighthood in the Order of the Netherlands Lion. As of 9 November 2026, his h-index is 113 in Google Scholar and 93 in Scopus, with 55,093 and 38,614 citations, respectively.

An enthusiastic educator and mentor, he is committed to turning imaging advances into earlier, more precise diagnosis and better-informed care for patients.

231 words. Suitable for a featured-speaker programme.

Professional profile

Clinical radiologist and translational imaging researcher with more than four decades of experience in urogenital MRI. His work spans image acquisition, interpretation, targeted biopsy, lymph node imaging and the implementation of diagnostic pathways. He combines clinical practice at Andros Clinics with international research collaborations and education.

Appointments and qualifications

Period	Appointment or qualification
2022–present	Emeritus Professor of Radiology, Radboudumc, Nijmegen
2022–present	Director of Imaging, Andros Clinics, Arnhem
1998–2022	Professor of Radiology, Radboudumc
2010–2022	Chair, Prostate MR Reference Center, Radboudumc
1985–2022	Faculty member, Department of Medical Imaging, Radboudumc
1981–1985	Radiology residency, Radboudumc
1990	PhD, Radboud University: Magnetic Resonance Imaging of Urinary Bladder Cancer
1980	MD, Utrecht University

Scientific contributions

Prostate MRI and PI-RADS. Contributed to ESUR prostate MRI guidelines and successive PI-RADS standards, supporting consistent acquisition, interpretation and reporting across centres.

MRI before biopsy. Co-authored prospective studies and diagnostic evidence supporting MRI-directed pathways and targeted biopsy, including the Dutch multicentre study reported by van der Leest and colleagues.

Macrophage and nanoparticle MRI. Advanced ferumoxtran-enhanced lymph node imaging, including MRI–histopathology correlation, ultrahigh-field imaging and economic modelling.

Image quality and artificial intelligence. Contributed to PI-QUAL version 2, the PI-CAI study, reader-performance research and ESUR guidance on prostate MRI quality.

Leadership education and professional service

- Imaging Editor, European Urology, listed since 2019.
- President, European Society of Urogenital Radiology, 2002–2004; former President of the International Cancer Imaging Society.
- Founder of the Prostate MR Reference Center and organiser of international prostate MRI teaching activities, including the fifth and twelfth ESUR Prostate Teaching Courses.
- Invited teaching at RSNA, EAU, AUA, ESUR, ICIS, SAR and SABI meetings, with an emphasis on interactive image interpretation and reporting quality.
- Mentor to more than 40 PhD candidates, as reported in the professional biography. The historical thesis register is retained in Appendix A.
- Contributions to Dutch prostate cancer guideline development and patient advocacy through the Prostaatkankerstichting.

Selected honours and awards

Year	Recognition
2026	Honorary Member, European Society of Urogenital Radiology (ESUR)
2023	Elected member, Academia Europaea
2022	ESUR Innovator in Urogenital Imaging Award
2020	EAU Innovators in Urology Award
2019	Honorary membership, Japanese Radiological Society and Polish Medical Radiological Society
2014	Knight in the Order of the Netherlands Lion
2012	Society of Abdominal Radiology Lifetime Achievement Award
2011	Wertheim–Salomonson Medal
2007	Queen Wilhelmina Research Award, Dutch Cancer Society; Fellow of ISMRM
2005	Fellow of the Society of Uroradiology, subsequently SAR
1999 and 2010	SCBTMR Lauterbur Award
1998	Fellow of SCBTMR, now SABI

Current research interests

Prostate MRI quality and reader training; AI-assisted cancer detection and MRI-based screening; ferumoxtran-enhanced macrophage MRI for nodal staging; and the diagnostic and economic consequences of imaging-led care. Experimental nanoparticle theranostics remains a research interest rather than an established clinical treatment.

Research output and citation metrics

Google Scholar and Scopus metrics were checked directly on the respective public author profiles on 9 November 2026. The PubMed search returned 347 results on the same date. The author-screened bibliography in Appendix B retains its retrieval date of 27 October 2026. Counts differ because the databases cover different document types and journals.

Source	h index	Output and verification
Scopus	93	378 documents; 38,614 citations from 21,030 citing documents. Directly verified 9 November 2026.
Google Scholar	113	55,093 citations; i10-index 297. All-time metrics directly verified 9 November 2026.
PubMed	Not applicable	347 search results on 9 November 2026. Appendix B contains 345 author-screened records retrieved 27 October 2026, excluding two J. H. Barentsz records. This is an indexed bibliography, not a count of original research articles.

Scopus profile: Jelle O. Barentsz 7006484477

Google Scholar profile: Jelle Barentsz Google Scholar

All-time h-indices are 113 in Google Scholar and 93 in Scopus. Google Scholar additionally reports 19,385 citations, an h-index of 57 and an i10-index of 171 for the period since 2021 (checked 9 November 2026). These recent-period figures should not be confused with the all-time metrics.

Recent publications

The bibliography includes 10 records with a 2026 journal date and six with a 2025 journal date. Letters, reviews, protocols and original studies are retained and should not be counted interchangeably. The complete PubMed-derived list is in Appendix B, with a direct link for every record.

Prostate cancer screening with MRI: insights from the ESUR Prostate MRI Working Group. Eur Radiol. 2026. PMID 42878808

Letter: Noninvasive Urine Test Predicts Grade Group Upgrading in Patients on Active Surveillance for Prostate Cancer: Multisite Validation and Comparison With MRI. J Urol. 2026. PMID 42808354

Cost-effectiveness of ferumoxtran-enhanced macrophage-specific-MRI and PSMA-PET/CT versus ePLND for nodal staging in primary prostate cancer: a decision analysis based on updated phase-3 trial data. J Med Econ. 2026. PMID 42464573

Sequential Imaging of Suspicion of Prostate Cancer: Reducing Overdiagnosis and Unnecessary Biopsy with Timely Diagnosis of Significant Cancer (SPROUT)-Prospective Multicentre Cohort Study Protocol. Eur Urol Oncol. 2026. PMID 42242939

Prostate MRI quality improvement: a Roadmap from the ESUR Prostate MRI Working Group. Eur Radiol. 2026. PMID 41826767

Letter to the Editor: Evaluation of an artificial intelligence model based on multiparametric transrectal ultrasound for localising clinically significant prostate cancer by simulation of targeted biopsies. Eur Radiol. 2026. PMID 41665651

Selected foundational publications

ESUR prostate MR guidelines 2012. Eur Radiol. 2012. PMID 22322308

Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med. 2003. PMID 12815134

PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. Eur Urol. 2016. PMID 26427566

Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. Eur Urol. 2019. PMID 30898406

Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study. Eur Urol. 2019. PMID 30477981

Artificial intelligence and radiologists in prostate cancer detection on MRI (PI-CAI): an international, paired, non-inferiority, confirmatory study. Lancet Oncol. 2024. PMID 38876123

Books and book chapters

Barentsz JO, Debruyne F, Ruijs JHJ, editors. Magnetic Resonance Imaging of Carcinoma of the Urinary Bladder. Kluwer Academic Publishers; 1990.

Bomers, Bittencourt, Villeirs, Barentsz. Chapter 39. In: Grainger and Allison's Diagnostic Radiology. 5th ed. 2008:931. Bibliographic details retained from the supplied CV.

Vermorken, Schrijvers, Weyler, Moreels, Carp, Barentsz, Heijmink. Diagnostiek in de oncologie. In: Oncologie. 8th ed. Bohn Stafleu van Loghum; 2011. Chapter 4:103.

Barentsz, Tekkis. Use of USPIOs for clinical lymph node imaging. In: Bulte, Modo, editors. Nanoparticles in Biomedical Imaging. Springer; 2008. Chapter 3:25.

Fortuin AS, Kwee TC, Bassu S, et al., including Barentsz JO. Assessment of lymph node detection and imaging in oncology. In: Aktolun C, Goldsmith SJ, editors. Nuclear Oncology. Wolters; 2015. Chapter 27:399.

Barentsz JO. Bladder cancer. In: Pollack HM, McClennan BL, editors. Clinical Urography. 2nd ed. Saunders; 2000. Chapter 48:1642.

Selected research funding

Historical awards and amounts below are retained from the supplied CV. They are not represented as currently active grants.

Project	Role and year	Reported funding
MAGNIFI	Main applicant; 2016	€126,800; Wesley Medical Research Institute and Garvan Research Institute
VALINODE ROF 1835	Main applicant; 2019	€149,500; Radboud Oncology Fund
ROF 1906 AI	Co-applicant; 2019	€40,000; Radboud Oncology Fund
ROF 2003 Theranostics	Co-applicant; 2019	€50,000; Radboud Oncology Fund
MRI and MR-guided biopsy in men with elevated PSA	Principal investigator; award 2015	€1,241,000; KWF 2015-6707
Queen Wilhelmina programme	Research leader; 2008–2014	€2,000,000; KWF

Earlier reported awards include CT versus USPIO-MRI for nodal staging (€1.2 million, 2002–2005) and four imaging projects listed at €250,000 each, covering haemodynamic contrast imaging, VEGF-related vascular imaging, contrast-enhanced MRI/ultrasound, and computer-assisted prostate cancer diagnosis. Amounts interpret the original K€ notation; original award documentation was not re-audited.

Professional relationships

The supplied CV lists advisory relationships with SPL Medical and Soteria Medical and translational involvement in ferumoxtran MRI and MRI-guided biopsy technology. These are retained as historical disclosures; current relationships should be confirmed for each speaker or journal disclosure form.

Appendix A Doctoral supervision

Historical register transcribed and deduplicated from the earlier CV, with completed doctorates for Bas Israël (2024), Ansje Fortuin (2025) and Esther Hamoen (2026) added. “Supervisor” and “co-supervisor” correspond to promotor and co-promotor. Historical dates and thesis titles are retained as recorded.

W. Morshuis — 1994. Surgical treatment of pectus excavatum. Indications and results. Co-supervisor.

PEJM Sallevelt — 1994. De substitutiewaarde van MRI inzake de preoperatieve diagnostiek van het Abdominale Arteriosclerotische Aneurysma.. Co-supervisor.

C Boetes — 1995. MR imaging in breast cancer, a clinical study. Co-supervisor.

D Franssen-Franken — 1996. Homocysteinaemie, treatment with vitamine D and folowup with MRI / MRA.. Co-supervisor.

PBJ van Vierzen — 1997. Fast Dynamic MRI of Gynecological Tumors. Co-supervisor.

AE Holland — 2000. Clinical and Experimental Cardiovascular MRA. Supervisor.

JW Goldfarb — 2000. Gd-enhanced MRI: Technical developments and Clinical Testing. Supervisor.

E Bos — 2003. Clinical Value of Analytes in Cyst Fluid from Ovarian Tumors. Supervisor.

M Engelbrecht — 2003. Local Staging of PCa using MRI. Supervisor.

JJ Futterer — 08-02-06. Advanced MRI Techniques in Localising and Local Staging of PCa.. Supervisor.

A Hovels — 10-02-08. The Value of MR-Lymphography in the Detection of Lymph Nodal Metastasis in Patients with PCa.. Supervisor.

S Broekhuis — 10-03-2010. Dynamic MRI in Female Pelvic Floor Disorders. Supervisor.

WMLLG Deserno — 22-12-2010. New Horizons in Lymph Node Imaging in Oncology. Supervisor.

J Veltman — 11-10-2010. Dynamic Contrast Enhanced MRI in the Classification of Breast Lesions. Supervisor.

RM Mann — 24-11-2010. The Effectiveness of Breast MRI in Invasive Lobular Carcinoma. Supervisor.

H Meijer — Not recorded. Magnetic resonance lymphography and lymph node irradiation in prostate cancer. Supervisor.

MJ Stoutjesdijk — 16-11-2011. Automated Analysis of Contrast Enhancement in MRI of the Breast. Supervisor.

PC Vos — 08-12-2011. Computer-aided Diagnosis of PCa with MRI. Supervisor.

C Meeuwis — 27-09-2011. Computer Aided Detection and Guided Biopsies using 3T MRI. Supervisor.

R Heesakkers — 25-01-2012. MR-lymphography in Prostate cancer. Supervisor.

T Hambrock — 04-12-2012. The value of 3T MRI for the Diagnosis and Aggressiveness Assessment of prostate cancer. Supervisor.

D. Yakar — 04-12-2012. MRI in localizing prostate Cancer (recurrence) and guided interventions. Supervisor.

D. Somford — 26-09-2013. Challenges in the diagnosis, grading and staging of prostate cancer. Supervisor.

C. Hoeks — 04-10-2013. Multiparametric MR imaging and MR guided biopsy: prostate cancer diagnosis and risk-stratification. Supervisor.

G Litjens — 23-01-2015. Computerized detection of cancer in multi-parametric prostate MRI. Supervisor.

S Heijmink — 24-06-2015. MR Imaging of Prostate Cancer at 3T: the Pros and Cons of Scanning with Endorectal Coil. Supervisor.

E Vos — 01-05-2016. Magnetic resonance imaging of prostate cancer: assessment of aggressiveness and pre-clinical developments. Supervisor.

W van de Ven — 04-07-2016. MRI guided TRUS prostate biopsy - a viable alternative?. Supervisor.

M Hoogenboom — 07-03-2017. MRI guided HiFu. Supervisor.

J Bomers — 06-06-2017. MR-guided focal therapy in patients with localized recurrent prostate cancer. Supervisor.

M. Schouten — 19-07-2017. MRI-guided prostate biopsy: which direction?. Supervisor.

K. Overduin — 18-12-2017. MRI-guided interventions for fast diagnosis and focal treatment of (recurrent) prostate cancer. Supervisor.

M de Rooij — 06-07-2017. Multiparametric MRI in prostate cancer. Supervisor.

W. Venderink — 11-12-2018. MRI and MRI-targeted biopsy of the prostate. The role of direct in-bore and MRI US fusion guided biospy. Supervisor.

Oscar Debats — 01-10-2020. Magnetic Resonance Lymphography. Supervisor.

Bart Philips — 27-10-2020. Methodological development of multiparametric, multimetabolic and USPIO-enhanced MRI at 7 Tesla for characterizing and staging prostate cancer. Supervisor.

Bas Israël — 2024. Completed doctorate.

Ansje Fortuin — 2025. Completed doctorate.

Esther Hamoen — 2026. Completed doctorate.

The earlier source also lists Patrik Zamecnik, Marloes van der Leest and Linda Thijssen as candidates. Their final defence dates and titles require confirmation before adding them to the completed register.

Appendix B PubMed publication record

345 records retrieved on 27 October 2026 using Barentsz J[Author], with author disambiguation. Two J. H. Barentsz records were excluded (PMIDs 23523126 and 2603694). Records are grouped by journal publication year, newest first; electronic publication may precede the issue date. The 2026 Journal of Medical Economics paper was published online on 16 July 2026 and assigned to the December issue.

Bibliographic titles and journal details follow PubMed. Author lists show the first six authors when longer, with Barentsz's authorship identified if not among those six. Corrections, letters and other indexed contributions are retained. This list does not claim to capture all non-PubMed publications.

2026

1. Brembilla G, Messina E, Barret T, Caglic I, Cuocolo R, de Rooij M, et al. Including Barentsz J. Prostate cancer screening with MRI: insights from the ESUR Prostate MRI Working Group. Eur Radiol. 2026. PubMed 42878808 DOI: 10.1007/s00330-026-12863-3

2. Ponsiglione A, Brembilla G, Barentsz J. Letter: Noninvasive Urine Test Predicts Grade Group Upgrading in Patients on Active Surveillance for Prostate Cancer: Multisite Validation and Comparison With MRI. J Urol. 2026:101097JU0000000000005310. PubMed 42808354 DOI: 10.1097/JU.0000000000005310

3. Zamecnik P, Feuerstein J, Berghahn M, Barentsz J. Cost-effectiveness of ferumoxtran-enhanced macrophage-specific-MRI and PSMA-PET/CT versus ePLND for nodal staging in primary prostate cancer: a decision analysis based on updated phase-3 trial data. J Med Econ. 2026;29(1):1974-1983. PubMed 42464573 DOI: 10.1080/13696998.2026.2699645

4. Sweere V, de Rooij M, Kil PJM, Israel B, van Basten JPA, Boellaard TN, et al. Including Barentsz JO. Sequential Imaging of Suspicion of Prostate Cancer: Reducing Overdiagnosis and Unnecessary Biopsy with Timely Diagnosis of Significant Cancer (SPROUT)-Prospective Multicentre Cohort Study Protocol. Eur Urol Oncol. 2026:S2588-9311(26)00153-7. PubMed 42242939 DOI: 10.1016/j.euo.2026.05.013

5. Dias AB, Barentsz J, Allen C, Baroni RH, Falińska H, Gaudiano C, et al. Prostate MRI quality improvement: a Roadmap from the ESUR Prostate MRI Working Group. Eur Radiol. 2026;36(7):5728-5744. PubMed 41826767 DOI: 10.1007/s00330-026-12395-w

6. Barentsz J, Immerzeel J, van der Leest M, Cornel E. Letter to the Editor: Evaluation of an artificial intelligence model based on multiparametric transrectal ultrasound for localising clinically significant prostate cancer by simulation of targeted biopsies. Eur Radiol. 2026;36(4):3050-3051. PubMed 41665651 DOI: 10.1007/s00330-026-12339-4

7. van den Kroonenberg DL, Barentsz J, Hamstra BJ, van den Bosch SM, Gijsbertsen JJ, Reitsma JB, et al. Real-world Inter-rater Agreement of PI-QUAL Version 2 for Prostate Magnetic Resonance Imaging Quality Assessment and Its Association with Diagnostic Accuracy. Eur Urol Open Sci. 2026;84:22-28. PubMed 41550796 DOI: 10.1016/j.euros.2025.12.019

8. Prinsen AMA, Wagensveld IM, Osses DF, Groenendijk PM, Zijta FM, Busstra MB, et al. Including Barentsz JO. Extending Current Guideline-recommended Prostate-specific Antigen Density Thresholds for Improving Benefit/Harm Balance in Risk-based Magnetic Resonance Imaging-directed Prostate Cancer Diagnosis, from the Community-based Multicentre MR-PROPER Study. Eur Urol Oncol. 2026;9(3):571-580. PubMed 41318235 DOI: 10.1016/j.euo.2025.11.002

9. Barentsz JO, Ahmed HU, Miszczyk M, Catalano C, Panebianco V. ESR Bridges: early-stage prostate cancer: new developments in imaging and treatment-a multidisciplinary view. Eur Radiol. 2026;36(4):3300-3302. PubMed 41201601 DOI: 10.1007/s00330-025-12125-8

10. Barentsz J, van Koeverden SW, van der Leest M. VI-RADS is not enough: why image quality is the key to reliable bladder cancer staging. Eur Radiol. 2026;36(2):1105-1107. PubMed 41125951 DOI: 10.1007/s00330-025-12086-y

2025

11. Hamoen EHJ, Israël B, van der Leest M, Cornel EB, Klaver OS, Hendriks RJ, et al. Including Barentsz JO. Impact of multiparametric MRI and prostate biopsies on anxiety and quality of life in men with suspected prostate cancer. BJUI Compass. 2025;6(10):e70087. PubMed 41111993 DOI: 10.1002/bco2.70087

12. Thijssen LCP, Twilt JJ, Barrett T, Giganti F, Schoots IG, Engels RRM, et al. Including Barentsz JO. Quality of prostate MRI in early diagnosis-a national survey and reading evaluation. Insights Imaging. 2025;16(1):82. PubMed 40188300 DOI: 10.1186/s13244-025-01960-4

13. Privé BM, Govers TM, Israël B, Janssen MJR, Timmermans BJR, Peters SMB, et al. Including Barentsz JO. A cost-effectiveness study of PSMA-PET/CT for the detection of clinically significant prostate cancer. Eur J Nucl Med Mol Imaging. 2025;52(9):3159-3169. PubMed 40072531 DOI: 10.1007/s00259-025-07190-6

14. Barentsz J, Thijssen L, Moore C, de Rooij M. Why quality matters in prostate-MR images: implementing PI-QUAL v2 for improved diagnosis and research. Eur Radiol. 2025;35(8):4927-4929. PubMed 39909900 DOI: 10.1007/s00330-025-11392-9

15. Villeirs G, Panebianco V, Moore CM, Barentsz JO. Re: Maarten De Rooij, Clare Allen, Jasper J. Twilt, et al. PI-QUAL Version 2: An Update of a Standardised Scoring System for the Assessment of Image Quality of Prostate MRI. Eur Radiol. In press. https://doi.org/10.1007/s00330-024-10795-4. Eur Urol. 2025;87(4):e72-e73. PubMed 39488466 DOI: 10.1016/j.eururo.2024.10.021

16. Twilt JJ, Saha A, Bosma JS, van Ginneken B, Bjartell A, Padhani AR, et al. Including Barentsz J. Evaluating Biparametric Versus Multiparametric Magnetic Resonance Imaging for Diagnosing Clinically Significant Prostate Cancer: An International, Paired, Noninferiority, Confirmatory Observer Study. Eur Urol. 2025;87(2):240-250. PubMed 39438187 DOI: 10.1016/j.eururo.2024.09.035

2024

17. Jager A, Oddens JR, Postema AW, Miclea RL, Schoots IG, Nooijen PGTA, et al. Including Barentsz JO. Is There an Added Value of Quantitative DCE-MRI by Magnetic Resonance Dispersion Imaging for Prostate Cancer Diagnosis? Cancers (Basel). 2024;16(13):2431. PubMed 39001493 DOI: 10.3390/cancers16132431

18. Saha A, Bosma JS, Twilt JJ, van Ginneken B, Bjartell A, Padhani AR, et al. Including Barentsz J. Artificial intelligence and radiologists in prostate cancer detection on MRI (PI-CAI): an international, paired, non-inferiority, confirmatory study. Lancet Oncol. 2024;25(7):879-887. PubMed 38876123 DOI: 10.1016/S1470-2045(24)00220-1

19. de Rooij M, Allen C, Twilt JJ, Thijssen LCP, Asbach P, Barrett T, et al. Including Barentsz J. PI-QUAL version 2: an update of a standardised scoring system for the assessment of image quality of prostate MRI. Eur Radiol. 2024;34(11):7068-7079. PubMed 38787428 DOI: 10.1007/s00330-024-10795-4

20. Ponsiglione A, Brembilla G, Cuocolo R, Gutierrez P, Moreira AS, Pecoraro M, et al. Including Barentsz J. ESR Essentials: using the right scoring system in prostate MRI-practice recommendations by ESUR. Eur Radiol. 2024;34(11):7481-7491. PubMed 38780764 DOI: 10.1007/s00330-024-10792-7

21. Privé BM, Israël B, Janssen MJR, van der Leest MMG, de Rooij M, van Ipenburg JA, et al. Including Barentsz JO. Multiparametric MRI and 18F-PSMA-1007 PET/CT for the Detection of Clinically Significant Prostate Cancer. Radiology. 2024;311(2):e231879. PubMed 38771185 DOI: 10.1148/radiol.231879

22. Duijn M, de Reijke TM, Barwari K, Hagens MJ, Rynja SP, Immerzeel J, et al. Including Barentsz JO. The association between patient and disease characteristics, and the risk of disease progression in patients with prostate cancer on active surveillance. World J Urol. 2024;42(1):87. PubMed 38372786 DOI: 10.1007/s00345-024-04805-9

23. Tenbergen CJA, Fortuin AS, van Asten JJA, Veltien A, Philips BWJ, Hambrock T, et al. Including Barentsz JO. The Potential of Iron Oxide Nanoparticle-Enhanced MRI at 7 T Compared With 3 T for Detecting Small Suspicious Lymph Nodes in Patients With Prostate Cancer. Invest Radiol. 2024;59(7):519-525. PubMed 38157433 DOI: 10.1097/RLI.0000000000001056

24. Panebianco V, Briganti A, Boellaard TN, Catto J, Comperat E, Efstathiou J, et al. Including Barentsz J. Clinical application of bladder MRI and the Vesical Imaging-Reporting and Data System. Nat Rev Urol. 2024;21(4):243-251. PubMed 38036666 DOI: 10.1038/s41585-023-00830-2

25. Schilham MGM, Somford DM, Veltien A, Zamecnik P, Barentsz JO, Sedelaar MJPM, et al. Subnodal Correspondence of PSMA Expression and USPIO-MRI in Metastatic Pelvic Lymph Nodes in Prostate Cancer. Invest Radiol. 2024;59(6):458-464. PubMed 37975702 DOI: 10.1097/RLI.0000000000001046

2023

26. Thijssen LCP, de Rooij M, Barentsz JO, Huisman HJ. Radiomics based automated quality assessment for T2W prostate MR images. Eur J Radiol. 2023;165:110928. PubMed 37354769 DOI: 10.1016/j.ejrad.2023.110928

27. Black R, Barentsz J, Howell D, Bostwick DG, Strum SB. Optimized 18F-FDG PET-CT Method to Improve Accuracy of Diagnosis of Metastatic Cancer. Diagnostics (Basel). 2023;13(9):1580. PubMed 37174971 DOI: 10.3390/diagnostics13091580

28. Schilham MGM, Rijpkema M, Scheenen T, Hermsen R, Barentsz JO, Sedelaar JPM, et al. Reply to Francesco Montorsi, Simone Scuderi, Alberto Briganti, and Giorgio Gandaglia's Letter to the Editor re: Melline G.M. Schilham, Mark Rijpkema, Tom Scheenen, et al. How Advanced Imaging Will Guide Therapeutic Strategies for Patients with Newly Diagnosed Prostate Cancer in the Years to Come. Eur Urol 2022;82:578-80. Eur Urol. 2023;83(5):e133-e134. PubMed 36781337 DOI: 10.1016/j.eururo.2023.01.023

29. Fortuin A, van Asten J, Veltien A, Philips B, Hambrock T, Johst S, et al. Including Barentsz J. Small Suspicious Lymph Nodes Detected on Ultrahigh-field Magnetic Resonance Imaging (MRI) in Patients with Prostate Cancer with High Risk of Nodal Metastases: The First In-patient Study on Ultrasmall Superparamagnetic Iron Oxide-enhanced 7T MRI. Eur Urol. 2023;83(4):375-377. PubMed 36739192 DOI: 10.1016/j.eururo.2023.01.002

30. Barrett T, de Rooij M, Giganti F, Allen C, Barentsz JO, Padhani AR. Quality checkpoints in the MRI-directed prostate cancer diagnostic pathway. Nat Rev Urol. 2023;20(1):9-22. PubMed 36168056 DOI: 10.1038/s41585-022-00648-4

31. Exterkate L, Wegelin O, Barentsz JO, van der Leest MG, Kummer JA, Vreuls W, et al. Incidence of significant prostate cancer after negative MRI and systematic biopsy in the FUTURE trial. BJU Int. 2023;131(3):313-320. PubMed 35993590 DOI: 10.1111/bju.15876

2022

32. Privé BM, Muselaers CHJ, van Oort IM, Janssen MJR, Peters SMB, van Gemert WAM, et al. Including Barentsz JO. An Update to the Pilot Study of 177Lu-PSMA in Low Volume Hormone-Sensitive Prostate Cancer. Front Nucl Med. 2022;2:863101. PubMed 39354959 DOI: 10.3389/fnume.2022.863101

33. Schilham MGM, Rijpkema M, Scheenen T, Hermsen R, Barentsz JO, Michiel Sedelaar JP, et al. How Advanced Imaging Will Guide Therapeutic Strategies for Patients with Newly Diagnosed Prostate Cancer in the Years to Come. Eur Urol. 2022;82(6):578-580. PubMed 36167598 DOI: 10.1016/j.eururo.2022.09.005

34. Israël B, Hannink G, Barentsz JO, van der Leest MMG. Implications of the European Association of Urology Recommended Risk Assessment Algorithm for Early Prostate Cancer Detection. Eur Urol Open Sci. 2022;43:1-4. PubMed 35845549 DOI: 10.1016/j.euros.2022.06.006

35. Pecoraro M, Turkbey B, Purysko AS, Girometti R, Giannarini G, Villeirs G, et al. Including Barentsz JO. Diagnostic Accuracy and Observer Agreement of the MRI Prostate Imaging for Recurrence Reporting Assessment Score. Radiology. 2022;304(2):342-350. PubMed 35536130 DOI: 10.1148/radiol.212252

36. Wagensveld IM, Osses DF, Groenendijk PM, Zijta FM, Busstra MB, Rociu E, et al. Including Barentsz JO. A Prospective Multicenter Comparison Study of Risk-adapted Ultrasound-directed and Magnetic Resonance Imaging-directed Diagnostic Pathways for Suspected Prostate Cancer in Biopsy-naïve Men. Eur Urol. 2022;82(3):318-326. PubMed 35341658 DOI: 10.1016/j.eururo.2022.03.003

37. Zamecnik P, Israel B, Feuerstein J, Nagarajah J, Gotthardt M, Barentsz JO, et al. Ferumoxtran-10-enhanced 3-T Magnetic Resonance Angiography of Pelvic Arteries: Initial Experience. Eur Urol Focus. 2022;8(6):1802-1808. PubMed 35337778 DOI: 10.1016/j.euf.2022.03.001

38. de Rooij M, van Poppel H, Barentsz JO. Risk Stratification and Artificial Intelligence in Early Magnetic Resonance Imaging-based Detection of Prostate Cancer. Eur Urol Focus. 2022;8(5):1187-1191. PubMed 34922897 DOI: 10.1016/j.euf.2021.11.005

39. de Rooij M, Barentsz JO. PI-QUAL v.1: the first step towards good-quality prostate MRI. Eur Radiol. 2022;32(2):876-878. PubMed 34842957 DOI: 10.1007/s00330-021-08399-3

40. Immerzeel J, Israël B, Bomers J, Schoots IG, van Basten JP, Kurth KH, et al. Including Barentsz J. Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 4: Transperineal Magnetic Resonance-Ultrasound Fusion Guided Biopsy Using Local Anesthesia. Eur Urol. 2022;81(1):110-117. PubMed 34799197 DOI: 10.1016/j.eururo.2021.10.032

41. Israël B, Immerzeel J, van der Leest M, Hannink G, Zámecnik P, Bomers J, et al. Including Barentsz J. Clinical implementation of pre-biopsy magnetic resonance imaging pathways for the diagnosis of prostate cancer. BJU Int. 2022;129(4):480-490. PubMed 34358388 DOI: 10.1111/bju.15562

2021

42. Fernandes CD, Mischi M, Wijkstra H, Barentsz JO, Heijmink SWTPJ, Turco S. Radiomic combination of spatial and temporal features extracted from DCE-MRI for prostate cancer detection. Annu Int Conf IEEE Eng Med Biol Soc. 2021;2021:3153-3156. PubMed 34891910 DOI: 10.1109/EMBC46164.2021.9630015

43. Privé BM, Janssen MJR, van Oort IM, Muselaers CHJ, Jonker MA, van Gemert WA, et al. Including Barentsz JO. Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial. Trials. 2021;22(1):768. PubMed 34736509 DOI: 10.1186/s13063-021-05733-4

44. Van Poppel H, Hogenhout R, Albers P, van den Bergh RCN, Barentsz JO, Roobol MJ. A European Model for an Organised Risk-stratified Early Detection Programme for Prostate Cancer. Eur Urol Oncol. 2021;4(5):731-739. PubMed 34364829 DOI: 10.1016/j.euo.2021.06.006

45. Padhani AR, Schoots IG, Barentsz JO. Fast Magnetic Resonance Imaging as a Viable Method for Directing the Prostate Cancer Diagnostic Pathway. Eur Urol Oncol. 2021;4(6):863-865. PubMed 34001458 DOI: 10.1016/j.euo.2021.04.009

46. Penzkofer T, Padhani AR, Turkbey B, Haider MA, Huisman H, Walz J, et al. Including Barentsz J. ESUR/ESUI position paper: developing artificial intelligence for precision diagnosis of prostate cancer using magnetic resonance imaging. Eur Radiol. 2021;31(12):9567-9578. PubMed 33991226 DOI: 10.1007/s00330-021-08021-6

47. Van Poppel H, Hogenhout R, Albers P, van den Bergh RCN, Barentsz JO, Roobol MJ. Reply to Laura Evangelista and Egesta Lopci's Letter to the Editor re: Hendrik Van Poppel, Renée Hogenhout, Peter Albers, et al. Early Detection of Prostate Cancer in 2020 and Beyond: Facts and Recommendations for the European Union and the European Commission. Eur Urol 2021;79:327-9: Early Detection of Prostate Cancer in High-risk Patients with Negative Fusion Biopsy. Eur Urol. 2021;80(1):e28-e29. PubMed 33965287 DOI: 10.1016/j.eururo.2021.04.027

48. Hendriks RJ, van der Leest MMG, Israël B, Hannink G, YantiSetiasti A, Cornel EB, et al. Including Barentsz JO. Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-naïve men. Prostate Cancer Prostatic Dis. 2021;24(4):1110-1119. PubMed 33941866 DOI: 10.1038/s41391-021-00367-8

49. Privé BM, Peters SMB, Muselaers CHJ, van Oort IM, Janssen MJR, Sedelaar JPM, et al. Including Barentsz JO. Lutetium-177-PSMA-617 in Low-Volume Hormone-Sensitive Metastatic Prostate Cancer: A Prospective Pilot Study. Clin Cancer Res. 2021;27(13):3595-3601. PubMed 33883176 DOI: 10.1158/1078-0432.CCR-20-4298

50. Panebianco V, Villeirs G, Weinreb JC, Turkbey BI, Margolis DJ, Richenberg J, et al. Including Barentsz JO. Prostate Magnetic Resonance Imaging for Local Recurrence Reporting (PI-RR): International Consensus -based Guidelines on Multiparametric Magnetic Resonance Imaging for Prostate Cancer Recurrence after Radiation Therapy and Radical Prostatectomy. Eur Urol Oncol. 2021;4(6):868-876. PubMed 33582104 DOI: 10.1016/j.euo.2021.01.003

51. Schilham MGM, Zamecnik P, Privé BM, Israël B, Rijpkema M, Scheenen T, et al. Including Barentsz JO. Head-to-Head Comparison of 68Ga-Prostate-Specific Membrane Antigen PET/CT and Ferumoxtran-10-Enhanced MRI for the Diagnosis of Lymph Node Metastases in Prostate Cancer Patients. J Nucl Med. 2021;62(9):1258-1263. PubMed 33517328 DOI: 10.2967/jnumed.120.258541

52. Van Poppel H, Hogenhout R, Albers P, van den Bergh RCN, Barentsz JO, Roobol MJ. Early Detection of Prostate Cancer in 2020 and Beyond: Facts and Recommendations for the European Union and the European Commission. Eur Urol. 2021;79(3):327-329. PubMed 33384200 DOI: 10.1016/j.eururo.2020.12.010

53. Padhani AR, Schoots IG, Turkbey B, Giannarini G, Barentsz JO. A multifaceted approach to quality in the MRI-directed biopsy pathway for prostate cancer diagnosis. Eur Radiol. 2021;31(6):4386-4389. PubMed 33241520 DOI: 10.1007/s00330-020-07527-9

54. Tempany-Afdhal CMC, Padhani A, Barentsz J, Weinreb J. Perspectives and Concerns about PI-RADS and Variability. Radiology. 2021;298(2):E112. PubMed 33231533 DOI: 10.1148/radiol.2020202340

55. Privé BM, Israël B, Schilham MGM, Muselaers CHJ, Zámecnik P, Mulders PFA, et al. Including Barentsz JO. Evaluating F-18-PSMA-1007-PET in primary prostate cancer and comparing it to multi-parametric MRI and histopathology. Prostate Cancer Prostatic Dis. 2021;24(2):423-430. PubMed 32999466 DOI: 10.1038/s41391-020-00292-2

56. Schoots IG, Barentsz JO, Bittencourt LK, Haider MA, Macura KJ, Margolis DJA, et al. PI-RADS Committee Position on MRI Without Contrast Medium in Biopsy-Naive Men With Suspected Prostate Cancer: Narrative Review. AJR Am J Roentgenol. 2021;216(1):3-19. PubMed 32812795 DOI: 10.2214/AJR.20.24268

2020

57. Raat HPJ, van Stiphout RSA, van Gorp ACF, Barentsz J. [Robot-controlled MRI-guided transrectal prostate biopsy, a promising technique]. Ned Tijdschr Geneeskd. 2020;164:D4815. PubMed 32940977

58. Privé BM, Janssen MJR, van Oort IM, Muselaers CHJ, Jonker MA, de Groot M, et al. Including Barentsz JO. Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial. BMC Cancer. 2020;20(1):884. PubMed 32928177 DOI: 10.1186/s12885-020-07386-z

59. Padhani AR, Barentsz J, Weinreb J, Schoots I, Tempany C. Re: Variability of the Positive Predictive Value of PI-RADS for Prostate MRI Across 26 Centers: Experience of the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel. Eur Urol. 2020;78(4):633-636. PubMed 32859439 DOI: 10.1016/j.eururo.2020.06.015

60. de Rooij M, Israël B, Barrett T, Giganti F, Padhani AR, Panebianco V, et al. Including Barentsz JO. Focus on the Quality of Prostate Multiparametric Magnetic Resonance Imaging: Synopsis of the ESUR/ESUI Recommendations on Quality Assessment and Interpretation of Images and Radiologists' Training. Eur Urol. 2020;78(4):483-485. PubMed 32591100 DOI: 10.1016/j.eururo.2020.06.023

61. Padhani AR, Villeirs G, Ahmed HU, Panebianco V, Schoots IG, Tempany CMC, et al. Including Barentsz JO. Platinum Opinion Counterview: The Evidence Base for the Benefit of Magnetic Resonance Imaging-directed Prostate Cancer Diagnosis is Sound. Eur Urol. 2020;78(3):307-309. PubMed 32540172 DOI: 10.1016/j.eururo.2020.05.038

62. de Rooij M, Israël B, Tummers M, Ahmed HU, Barrett T, Giganti F, et al. Including Barentsz JO. ESUR/ESUI consensus statements on multi-parametric MRI for the detection of clinically significant prostate cancer: quality requirements for image acquisition, interpretation and radiologists' training. Eur Radiol. 2020;30(10):5404-5416. PubMed 32424596 DOI: 10.1007/s00330-020-06929-z

63. de Rooij M, Israël B, Bomers JGR, Schoots IG, Barentsz JO. Can Biparametric Prostate Magnetic Resonance Imaging Fulfill its PROMIS? Eur Urol. 2020;78(4):512-514. PubMed 32416975 DOI: 10.1016/j.eururo.2020.04.062

64. Westphalen AC, McCulloch CE, Anaokar JM, Arora S, Barashi NS, Barentsz JO, et al. Variability of the Positive Predictive Value of PI-RADS for Prostate MRI across 26 Centers: Experience of the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel. Radiology. 2020;296(1):76-84. PubMed 32315265 DOI: 10.1148/radiol.2020190646

65. Stabile A, Giganti F, Kasivisvanathan V, Giannarini G, Moore CM, Padhani AR, et al. Including Barentsz JO. Factors Influencing Variability in the Performance of Multiparametric Magnetic Resonance Imaging in Detecting Clinically Significant Prostate Cancer: A Systematic Literature Review. Eur Urol Oncol. 2020;3(2):145-167. PubMed 32192942 DOI: 10.1016/j.euo.2020.02.005

66. Leest MV, Israël B, Engels RRM, Barentsz JO. Reply to Arnaldo Stanzione, Massimo Imbriaco, and Renato Cuocolo's Letter to the Editor re: Marloes van der Leest, Bas Israël, Eric Bastiaan Cornel, et al. High Diagnostic Performance of Short Magnetic Resonance Imaging Protocols for Prostate Cancer Detection in Biopsy-naïve Men: The Next Step in Magnetic Resonance Imaging Accessibility. Eur Urol 2019;76:574-81. Are We Meeting Our Standards? Stringent Prostate Imaging Reporting and Data System Acquisition Requirements Might be Limiting Prostate Accessibility. Eur Urol. 2020;77(3):e58-e59. PubMed 31818520 DOI: 10.1016/j.eururo.2019.11.016

67. Venderink W, Bomers JG, Overduin CG, Padhani AR, de Lauw GR, Sedelaar MJ, et al. Including Barentsz JO. Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 3: Targeted Biopsy. Eur Urol. 2020;77(4):481-490. PubMed 31791623 DOI: 10.1016/j.eururo.2019.10.009

68. Israël B, Leest MV, Sedelaar M, Padhani AR, Zámecnik P, Barentsz JO. Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 2: Interpretation. Eur Urol. 2020;77(4):469-480. PubMed 31767492 DOI: 10.1016/j.eururo.2019.10.024

69. Schoots IG, Padhani AR, Rouvière O, Barentsz JO, Richenberg J. Analysis of Magnetic Resonance Imaging-directed Biopsy Strategies for Changing the Paradigm of Prostate Cancer Diagnosis. Eur Urol Oncol. 2020;3(1):32-41. PubMed 31706946 DOI: 10.1016/j.euo.2019.10.001

70. Engels RRM, Israël B, Padhani AR, Barentsz JO. Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 1: Acquisition. Eur Urol. 2020;77(4):457-468. PubMed 31582290 DOI: 10.1016/j.eururo.2019.09.021

71. Exterkate L, Wegelin O, Barentsz JO, van der Leest MG, Kummer JA, Vreuls W, et al. Is There Still a Need for Repeated Systematic Biopsies in Patients with Previous Negative Biopsies in the Era of Magnetic Resonance Imaging-targeted Biopsies of the Prostate? Eur Urol Oncol. 2020;3(2):216-223. PubMed 31239236 DOI: 10.1016/j.euo.2019.06.005

72. Scholte M, Barentsz JO, Sedelaar JPM, Gotthardt M, Grutters JPC, Rovers MM. Modelling Study with an Interactive Model Assessing the Cost-effectiveness of 68Ga Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Nano Magnetic Resonance Imaging for the Detection of Pelvic Lymph Node Metastases in Patients with Primary Prostate Cancer. Eur Urol Focus. 2020;6(5):967-974. PubMed 30826284 DOI: 10.1016/j.euf.2019.02.013

2019

73. Westdorp H, Creemers JHA, van Oort IM, Schreibelt G, Gorris MAJ, Mehra N, et al. Including Barentsz JO. Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer. J Immunother Cancer. 2019;7(1):302. PubMed 31727154 DOI: 10.1186/s40425-019-0787-6

74. Wegelin O, Exterkate L, van der Leest M, Kelder JC, Bosch JLHR, Barentsz JO, et al. Complications and Adverse Events of Three Magnetic Resonance Imaging-based Target Biopsy Techniques in the Diagnosis of Prostate Cancer Among Men with Prior Negative Biopsies: Results from the FUTURE Trial, a Multicentre Randomised Controlled Trial. Eur Urol Oncol. 2019;2(6):617-624. PubMed 31519516 DOI: 10.1016/j.euo.2019.08.007

75. Barentsz JO, van der Leest MMG, Israël B. Reply to Jochen Walz. Let's Keep It at One Step at a Time: Why Biparametric Magnetic Resonance Imaging Is Not the Priority Today. Eur Urol 2019;76:582-3: How to Implement High-quality, High-volume Prostate Magnetic Resonance Imaging: Gd Contrast Can Help but Is Not the Major Issue. Eur Urol. 2019;76(5):584-585. PubMed 31409496 DOI: 10.1016/j.eururo.2019.07.039

76. Venderink W, van Luijtelaar A, van der Leest M, Barentsz JO, Jenniskens SFM, Sedelaar MJP, et al. Multiparametric magnetic resonance imaging and follow-up to avoid prostate biopsy in 4259 men. BJU Int. 2019;124(5):775-784. PubMed 31237388 DOI: 10.1111/bju.14853

77. Philips BWJ, Stijns RCH, Rietsch SHG, Brunheim S, Barentsz JO, Fortuin AS, et al. USPIO-enhanced MRI of pelvic lymph nodes at 7-T: preliminary experience. Eur Radiol. 2019;29(12):6529-6538. PubMed 31201525 DOI: 10.1007/s00330-019-06277-7

78. Padhani AR, Barentsz J, Villeirs G, Rosenkrantz AB, Margolis DJ, Turkbey B, et al. PI-RADS Steering Committee: The PI-RADS Multiparametric MRI and MRI-directed Biopsy Pathway. Radiology. 2019;292(2):464-474. PubMed 31184561 DOI: 10.1148/radiol.2019182946

79. Rosenkrantz AB, Turkbey B, Barentsz J, Weinreb JC. Reply to Byung Kwan Park's Letter to the Editor re: Baris Turkbey, Andrew B. Rosenkrantz, Masoom A. Haider, et al. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. Eur Urol 2019;76:329-40. Eur Urol. 2019;76(3):e79. PubMed 31182228 DOI: 10.1016/j.eururo.2019.05.039

80. van der Leest M, Israël B, Cornel EB, Zámecnik P, Schoots IG, van der Lelij H, et al. Including Barentsz J. High Diagnostic Performance of Short Magnetic Resonance Imaging Protocols for Prostate Cancer Detection in Biopsy-naïve Men: The Next Step in Magnetic Resonance Imaging Accessibility. Eur Urol. 2019;76(5):574-581. PubMed 31167748 DOI: 10.1016/j.eururo.2019.05.029

81. Turkbey B, Rosenkrantz AB, Haider MA, Padhani AR, Villeirs G, Macura KJ, et al. Including Barentsz J. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. Eur Urol. 2019;76(3):340-351. PubMed 30898406 DOI: 10.1016/j.eururo.2019.02.033

82. Padhani AR, Haider MA, Villers A, Barentsz JO. Multiparametric Magnetic Resonance Imaging for Prostate Cancer Detection: What We See and What We Miss. Eur Urol. 2019;75(5):721-722. PubMed 30563723 DOI: 10.1016/j.eururo.2018.12.004

83. Wegelin O, Exterkate L, van der Leest M, Kummer JA, Vreuls W, de Bruin PC, et al. Including Barentsz JO. The FUTURE Trial: A Multicenter Randomised Controlled Trial on Target Biopsy Techniques Based on Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer in Patients with Prior Negative Biopsies. Eur Urol. 2019;75(4):582-590. PubMed 30522912 DOI: 10.1016/j.eururo.2018.11.040

84. van der Leest M, Cornel E, Israël B, Hendriks R, Padhani AR, Hoogenboom M, et al. Including Barentsz JO. Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study. Eur Urol. 2019;75(4):570-578. PubMed 30477981 DOI: 10.1016/j.eururo.2018.11.023

85. Panebianco V, Barentsz J, Narumi Y, Catto JWF. Reply to Jeremy Y.C. Teoh, Thomas R.W. Herrmann, and Marek Babjuk's Letter to the Editor re: Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting and Data System). Eur Urol 2018;74:294-306. Eur Urol. 2019;75(2):e29-e30. PubMed 30471881 DOI: 10.1016/j.eururo.2018.09.032

86. Padhani AR, Weinreb J, Rosenkrantz AB, Villeirs G, Turkbey B, Barentsz J. Prostate Imaging-Reporting and Data System Steering Committee: PI-RADS v2 Status Update and Future Directions. Eur Urol. 2019;75(3):385-396. PubMed 29908876 DOI: 10.1016/j.eururo.2018.05.035

87. Hamoen EHJ, Hoeks CMA, Somford DM, van Oort IM, Vergunst H, Oddens JR, et al. Including Barentsz JO. Value of Serial Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging-guided Biopsies in Men with Low-risk Prostate Cancer on Active Surveillance After 1 Yr Follow-up. Eur Urol Focus. 2019;5(3):407-415. PubMed 29331622 DOI: 10.1016/j.euf.2017.12.008

2018

88. Turco S, Lavini C, Heijmink S, Barentsz J, Wijkstra H, Mischi M. Evaluation of Dispersion MRI for Improved Prostate Cancer Diagnosis in a Multicenter Study. AJR Am J Roentgenol. 2018;211(5):W242-W251. PubMed 30346837 DOI: 10.2214/AJR.17.19215

89. Panebianco V, Barentsz J, Narumi Y, Catto J, VI-RADS authors. Reply to Andrea Necchi, Antonella Messina, and Alberto Briganti's Letter to the Editor re: Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting and Data System). Eur Urol 2018;74:294-306. Eur Urol. 2018;74(5):e109. PubMed 30029821 DOI: 10.1016/j.eururo.2018.06.029

90. Overduin CG, Heidkamp J, Rothgang E, Barentsz JO, de Lange F, Fütterer JJ. Fast 3-T MR-guided transrectal prostate biopsy using an in-room tablet device for needle guide alignment: a feasibility study. Eur Radiol. 2018;28(11):4824-4831. PubMed 29789909 DOI: 10.1007/s00330-018-5497-9

91. Panebianco V, Narumi Y, Altun E, Bochner BH, Efstathiou JA, Hafeez S, et al. Including Barentsz J. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). Eur Urol. 2018;74(3):294-306. PubMed 29755006 DOI: 10.1016/j.eururo.2018.04.029

92. Alberts AR, Schoots IG, Bokhorst LP, Drost FH, van Leenders GJ, Krestin GP, et al. Including Barentsz JO. Characteristics of Prostate Cancer Found at Fifth Screening in the European Randomized Study of Screening for Prostate Cancer Rotterdam: Can We Selectively Detect High-grade Prostate Cancer with Upfront Multivariable Risk Stratification and Magnetic Resonance Imaging? Eur Urol. 2018;73(3):343-350. PubMed 28647216 DOI: 10.1016/j.eururo.2017.06.019

93. Fortuin AS, Brüggemann R, van der Linden J, Panfilov I, Israël B, Scheenen TWJ, et al. Including Barentsz JO. Ultra-small superparamagnetic iron oxides for metastatic lymph node detection: back on the block. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2018;10(1):e1471. PubMed 28382713 DOI: 10.1002/wnan.1471

94. Venderink W, van Luijtelaar A, Bomers JGR, van der Leest M, Hulsbergen-van de Kaa C, Barentsz JO, et al. Results of Targeted Biopsy in Men with Magnetic Resonance Imaging Lesions Classified Equivocal, Likely or Highly Likely to Be Clinically Significant Prostate Cancer. Eur Urol. 2018;73(3):353-360. PubMed 28258784 DOI: 10.1016/j.eururo.2017.02.021

2017

95. Hendriks RJ, van der Leest MMG, Dijkstra S, Barentsz JO, Van Criekinge W, Hulsbergen-van de Kaa CA, et al. A urinary biomarker-based risk score correlates with multiparametric MRI for prostate cancer detection. Prostate. 2017;77(14):1401-1407. PubMed 28853167 DOI: 10.1002/pros.23401

96. Mus RD, Borelli C, Bult P, Weiland E, Karssemeijer N, Barentsz JO, et al. Time to enhancement derived from ultrafast breast MRI as a novel parameter to discriminate benign from malignant breast lesions. Eur J Radiol. 2017;89:90-96. PubMed 28267555 DOI: 10.1016/j.ejrad.2017.01.020

97. Barentsz J, de Rooij M, Villeirs G, Weinreb J. Prostate Imaging-Reporting and Data System Version 2 and the Implementation of High-quality Prostate Magnetic Resonance Imaging. Eur Urol. 2017;72(2):189-191. PubMed 28262414 DOI: 10.1016/j.eururo.2017.02.030

98. van Leeuwen PJ, Hayen A, Thompson JE, Moses D, Shnier R, Böhm M, et al. Including Barentsz J. A multiparametric magnetic resonance imaging-based risk model to determine the risk of significant prostate cancer prior to biopsy. BJU Int. 2017;120(6):774-781. PubMed 28207981 DOI: 10.1111/bju.13814

99. Schouten MG, van der Leest M, Pokorny M, Hoogenboom M, Barentsz JO, Thompson LC, et al. Why and Where do We Miss Significant Prostate Cancer with Multi-parametric Magnetic Resonance Imaging followed by Magnetic Resonance-guided and Transrectal Ultrasound-guided Biopsy in Biopsy-naïve Men? Eur Urol. 2017;71(6):896-903. PubMed 28063613 DOI: 10.1016/j.eururo.2016.12.006

100. Barentsz JO, Mulders P, Gerritsen W, Fütterer JJ. Assessing Metastatic Disease in Advanced Prostate Cancer: It's Time to Change Imaging. Eur Urol. 2017;71(1):93-95. PubMed 27595376 DOI: 10.1016/j.eururo.2016.08.045

101. Wegelin O, van Melick HHE, Hooft L, Bosch JLHR, Reitsma HB, Barentsz JO, et al. Comparing Three Different Techniques for Magnetic Resonance Imaging-targeted Prostate Biopsies: A Systematic Review of In-bore versus Magnetic Resonance Imaging-transrectal Ultrasound fusion versus Cognitive Registration. Is There a Preferred Technique? Eur Urol. 2017;71(4):517-531. PubMed 27568655 DOI: 10.1016/j.eururo.2016.07.041

102. Bomers JGR, Cornel EB, Fütterer JJ, Jenniskens SFM, Schaafsma HE, Barentsz JO, et al. MRI-guided focal laser ablation for prostate cancer followed by radical prostatectomy: correlation of treatment effects with imaging. World J Urol. 2017;35(5):703-711. PubMed 27541586 DOI: 10.1007/s00345-016-1924-1

2016

103. Debats OA, Fortuin AS, Meijer HJ, Hambrock T, Litjens GJ, Barentsz JO, et al. Intranodal signal suppression in pelvic MR lymphography of prostate cancer patients: a quantitative comparison of ferumoxtran-10 and ferumoxytol. PeerJ. 2016;4:e2471. PubMed 27781154 DOI: 10.7717/peerj.2471

104. Purysko AS, Rosenkrantz AB, Barentsz JO, Weinreb JC, Macura KJ. PI-RADS Version 2: A Pictorial Update. Radiographics. 2016;36(5):1354-72. PubMed 27471952 DOI: 10.1148/rg.2016150234

105. van de Ven WJ, Sedelaar JP, van der Leest MM, Hulsbergen-van de Kaa CA, Barentsz JO, Fütterer JJ, et al. Visibility of prostate cancer on transrectal ultrasound during fusion with multiparametric magnetic resonance imaging for biopsy. Clin Imaging. 2016;40(4):745-50. PubMed 27317220 DOI: 10.1016/j.clinimag.2016.02.005

106. Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, Margolis D, et al. Reply to Erik Rud and Eduard Baco's Letter to the Editor re: Re: Jeffrey C. Weinreb, Jelle O. Barentsz, Peter L. Choyke, et al. PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. Eur Urol 2016;69:16-40. Eur Urol. 2016;70(5):e137-e138. PubMed 27130148 DOI: 10.1016/j.eururo.2016.04.016

107. van de Ven WJ, Venderink W, Sedelaar JP, Veltman J, Barentsz JO, Fütterer JJ, et al. MR-targeted TRUS prostate biopsy using local reference augmentation: initial experience. Int Urol Nephrol. 2016;48(7):1037-45. PubMed 27068817 DOI: 10.1007/s11255-016-1283-2

108. Weinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, et al. PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. Eur Urol. 2016;69(1):16-40. PubMed 26427566 DOI: 10.1016/j.eururo.2015.08.052

109. Barentsz JO, Weinreb JC, Verma S, Thoeny HC, Tempany CM, Shtern F, et al. Synopsis of the PI-RADS v2 Guidelines for Multiparametric Prostate Magnetic Resonance Imaging and Recommendations for Use. Eur Urol. 2016;69(1):41-9. PubMed 26361169 DOI: 10.1016/j.eururo.2015.08.038

110. de Rooij M, Hamoen EH, Witjes JA, Barentsz JO, Rovers MM. Accuracy of Magnetic Resonance Imaging for Local Staging of Prostate Cancer: A Diagnostic Meta-analysis. Eur Urol. 2016;70(2):233-45. PubMed 26215604 DOI: 10.1016/j.eururo.2015.07.029

111. Litjens GJ, Elliott R, Shih NN, Feldman MD, Kobus T, Hulsbergen-van de Kaa C, et al. Including Barentsz JO. Computer-extracted Features Can Distinguish Noncancerous Confounding Disease from Prostatic Adenocarcinoma at Multiparametric MR Imaging. Radiology. 2016;278(1):135-45. PubMed 26192734 DOI: 10.1148/radiol.2015142856

2015

112. Barentsz J, Futterer JJ, Padhani AR. Will Magnetic Resonance Imaging-guided Biopsy Replace Systematic Biopsy? Eur Urol Focus. 2015;1(2):152-155. PubMed 28723427 DOI: 10.1016/j.euf.2015.07.008

113. Panebianco V, Barchetti F, Barentsz J, Ciardi A, Cornud F, Futterer J, et al. Pitfalls in Interpreting mp-MRI of the Prostate: A Pictorial Review with Pathologic Correlation. Insights Imaging. 2015;6(6):611-30. PubMed 26385690 DOI: 10.1007/s13244-015-0426-9

114. Schouten MG, Hoeks CM, Bomers JG, Hulsbergen-van de Kaa CA, Witjes JA, Thompson LC, et al. Including Barentsz JO. Location of Prostate Cancers Determined by Multiparametric and MRI-Guided Biopsy in Patients With Elevated Prostate-Specific Antigen Level and at Least One Negative Transrectal Ultrasound-Guided Biopsy. AJR Am J Roentgenol. 2015;205(1):57-63. PubMed 26102380 DOI: 10.2214/AJR.14.12960

115. Litjens GJ, Barentsz JO, Karssemeijer N, Huisman HJ. Clinical evaluation of a computer-aided diagnosis system for determining cancer aggressiveness in prostate MRI. Eur Radiol. 2015;25(11):3187-99. PubMed 26060063 DOI: 10.1007/s00330-015-3743-y

116. van de Ven WJ, Hu Y, Barentsz JO, Karssemeijer N, Barratt D, Huisman HJ. Biomechanical modeling constrained surface-based image registration for prostate MR guided TRUS biopsy. Med Phys. 2015;42(5):2470-81. PubMed 25979040 DOI: 10.1118/1.4917481

117. Barentsz JO, Thoeny HC. Prostate cancer: Can imaging accurately diagnose lymph node involvement? Nat Rev Urol. 2015;12(6):313-5. PubMed 25941790 DOI: 10.1038/nrurol.2015.91

118. Vos EK, Kobus T, Litjens GJ, Hambrock T, Hulsbergen-van de Kaa CA, Barentsz JO, et al. Multiparametric Magnetic Resonance Imaging for Discriminating Low-Grade From High-Grade Prostate Cancer. Invest Radiol. 2015;50(8):490-7. PubMed 25867656 DOI: 10.1097/RLI.0000000000000157

119. Kayat Bittencourt L, Litjens G, Hulsbergen-van de Kaa CA, Turkbey B, Gasparetto EL, Barentsz JO. Prostate Cancer: The European Society of Urogenital Radiology Prostate Imaging Reporting and Data System Criteria for Predicting Extraprostatic Extension by Using 3-T Multiparametric MR Imaging. Radiology. 2015;276(2):479-89. PubMed 25848900 DOI: 10.1148/radiol.15141412

120. Hamoen EHJ, de Rooij M, Witjes JA, Barentsz JO, Rovers MM. Use of the Prostate Imaging Reporting and Data System (PI-RADS) for Prostate Cancer Detection with Multiparametric Magnetic Resonance Imaging: A Diagnostic Meta-analysis. Eur Urol. 2015;67(6):1112-1121. PubMed 25466942 DOI: 10.1016/j.eururo.2014.10.033

121. Pokorny M, Van de Ven W, Barentsz J, Thompson L. Reply to Yaalini Shanmugabavan, Stephanie Guillaumier and Hashim U. Ahmed's letter to the editor re: Morgan R. Pokorny, Maarten de Rooij, Earl Duncan, et al. Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies. Eur Urol 2014;66:22-9. Eur Urol. 2015;67(3):e54-5. PubMed 25194908 DOI: 10.1016/j.eururo.2014.08.066

122. Hamoen EH, De Rooij M, Witjes JA, Barentsz JO, Rovers MM. Measuring health-related quality of life in men with prostate cancer: A systematic review of the most used questionnaires and their validity. Urol Oncol. 2015;33(2):69.e19-28. PubMed 24433753 DOI: 10.1016/j.urolonc.2013.10.005

2014

123. Bittencourt LK, Hausmann D, Sabaneeff N, Gasparetto EL, Barentsz JO. Multiparametric magnetic resonance imaging of the prostate: current concepts. Radiol Bras. 2014;47(5):292-300. PubMed 25741104 DOI: 10.1590/0100-3984.2013.1863

124. Zamecnik P, Schouten MG, Krafft AJ, Maier F, Schlemmer HP, Barentsz JO, et al. Automated real-time needle-guide tracking for fast 3-T MR-guided transrectal prostate biopsy: a feasibility study. Radiology. 2014;273(3):879-86. PubMed 25061830 DOI: 10.1148/radiol.14132067

125. van Niekerk CG, van der Laak JA, Hambrock T, Huisman HJ, Witjes JA, Barentsz JO, et al. Correlation between dynamic contrast-enhanced MRI and quantitative histopathologic microvascular parameters in organ-confined prostate cancer. Eur Radiol. 2014;24(10):2597-605. PubMed 25033819 DOI: 10.1007/s00330-014-3301-z

126. Bomers JG, Barentsz JO. Standardization of multiparametric prostate MR imaging using PI-RADS. Biomed Res Int. 2014;2014:431680. PubMed 25003112 DOI: 10.1155/2014/431680

127. Vos EK, Lagemaat MW, Barentsz JO, Fütterer JJ, Zámecnik P, Roozen H, et al. Image quality and cancer visibility of T2-weighted magnetic resonance imaging of the prostate at 7 Tesla. Eur Radiol. 2014;24(8):1950-8. PubMed 24865699 DOI: 10.1007/s00330-014-3234-6

128. de Rooij M, Crienen S, Witjes JA, Barentsz JO, Rovers MM, Grutters JP. Reply to Sarah Willis, Alec Miners, and Jan van der Meulen's letter to the editor re: Maarten de Rooij, Simone Crienen, J. Alfred Witjes, Jelle O. Barentsz, Maroeska M. Rovers, Janneke P.C. Grutters. Cost-effectiveness of magnetic resonance (MR) imaging and MR-guided targeted biopsy versus systematic transrectal ultrasound-guided biopsy in diagnosing prostate cancer: a modelling study from a health care perspective. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2013.12.012. Eur Urol. 2014;66(2):e30. PubMed 24837186 DOI: 10.1016/j.eururo.2014.04.012

129. Litjens G, Debats O, Barentsz J, Karssemeijer N, Huisman H. Computer-aided detection of prostate cancer in MRI. IEEE Trans Med Imaging. 2014;33(5):1083-92. PubMed 24770913 DOI: 10.1109/TMI.2014.2303821

130. Pokorny MR, de Rooij M, Duncan E, Schröder FH, Parkinson R, Barentsz JO, et al. Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies. Eur Urol. 2014;66(1):22-9. PubMed 24666839 DOI: 10.1016/j.eururo.2014.03.002

131. Schröder FH, Venderbos LD, van den Bergh RC, Hessels D, van Leenders GJ, van Leeuwen PJ, et al. Including Barentsz JO. Prostate cancer antigen 3: diagnostic outcomes in men presenting with urinary prostate cancer antigen 3 scores ≥100. Urology. 2014;83(3):613-6. PubMed 24581524 DOI: 10.1016/j.urology.2013.12.005

132. de Rooij M, Hamoen EH, Fütterer JJ, Barentsz JO, Rovers MM. Accuracy of multiparametric MRI for prostate cancer detection: a meta-analysis. AJR Am J Roentgenol. 2014;202(2):343-51. PubMed 24450675 DOI: 10.2214/AJR.13.11046

133. Fortuin AS, Smeenk RJ, Meijer HJ, Witjes AJ, Barentsz JO. Lymphotropic nanoparticle-enhanced MRI in prostate cancer: value and therapeutic potential. Curr Urol Rep. 2014;15(3):389. PubMed 24430170 DOI: 10.1007/s11934-013-0389-7

134. Leake JL, Hardman R, Ojili V, Thompson I, Shanbhogue A, Hernandez J, et al. Including Barentsz J. Prostate MRI: access to and current practice of prostate MRI in the United States. J Am Coll Radiol. 2014;11(2):156-60. PubMed 24389134 DOI: 10.1016/j.jacr.2013.05.006

135. de Rooij M, Crienen S, Witjes JA, Barentsz JO, Rovers MM, Grutters JP. Cost-effectiveness of magnetic resonance (MR) imaging and MR-guided targeted biopsy versus systematic transrectal ultrasound-guided biopsy in diagnosing prostate cancer: a modelling study from a health care perspective. Eur Urol. 2014;66(3):430-6. PubMed 24377803 DOI: 10.1016/j.eururo.2013.12.012

136. Hoeks CM, Somford DM, van Oort IM, Vergunst H, Oddens JR, Smits GA, et al. Including Barentsz JO. Value of 3-T multiparametric magnetic resonance imaging and magnetic resonance-guided biopsy for early risk restratification in active surveillance of low-risk prostate cancer: a prospective multicenter cohort study. Invest Radiol. 2014;49(3):165-72. PubMed 24220253 DOI: 10.1097/RLI.0000000000000008

2013

137. Hamoen EH, Reukers DF, Numans ME, Barentsz JO, Witjes JA, Rovers MM. Discrepancies between guidelines and clinical practice regarding prostate-specific antigen testing. Fam Pract. 2013;30(6):648-54. PubMed 24107269 DOI: 10.1093/fampra/cmt045

138. Fortuin AS, Meijer H, Thompson LC, Witjes JA, Barentsz JO. Ferumoxtran-10 ultrasmall superparamagnetic iron oxide-enhanced diffusion-weighted imaging magnetic resonance imaging for detection of metastases in normal-sized lymph nodes in patients with bladder and prostate cancer: do we enter the era after extended pelvic lymph node dissection? Eur Urol. 2013;64(6):961-3; discussion 963. PubMed 23972400 DOI: 10.1016/j.eururo.2013.08.017

139. van de Ven WJ, Barentsz JO. Prostate cancer: MRI/US-guided biopsy--a viable alternative to TRUS-guidance. Nat Rev Urol. 2013;10(10):559-60. PubMed 23938941 DOI: 10.1038/nrurol.2013.179

140. Meijer HJ, Debats OA, van Lin EN, Witjes JA, Kaanders JH, Barentsz JO. A retrospective analysis of the prognosis of prostate cancer patients with lymph node involvement on MR lymphography: who might be cured. Radiat Oncol. 2013;8:190. PubMed 23898991 DOI: 10.1186/1748-717X-8-190

141. Fortuin A, Rooij Md, Zamecnik P, Haberkorn U, Barentsz J. Molecular and functional imaging for detection of lymph node metastases in prostate cancer. Int J Mol Sci. 2013;14(7):13842-75. PubMed 23823804 DOI: 10.3390/ijms140713842

142. Leyten GH, Wierenga EA, Sedelaar JP, van Oort IM, Futterer JJ, Barentsz JO, et al. Value of PCA3 to predict biopsy outcome and its potential role in selecting patients for multiparametric MRI. Int J Mol Sci. 2013;14(6):11347-55. PubMed 23759986 DOI: 10.3390/ijms140611347

143. Barentsz J, Villers A, Schouten M. ESUR prostate MR guidelines. Author reply. Eur Radiol. 2013;23(8):2322-3. PubMed 23754463 DOI: 10.1007/s00330-013-2896-9

144. Vos EK, Litjens GJ, Kobus T, Hambrock T, Hulsbergen-van de Kaa CA, Barentsz JO, et al. Assessment of prostate cancer aggressiveness using dynamic contrast-enhanced magnetic resonance imaging at 3 T. Eur Urol. 2013;64(3):448-55. PubMed 23751135 DOI: 10.1016/j.eururo.2013.05.045

145. Meijer HJ, Debats OA, Th van Lin EN, van Vulpen M, Witjes JA, Oyen WJ, et al. Including Barentsz JO. Individualized image-based lymph node irradiation for prostate cancer. Nat Rev Urol. 2013;10(7):376-85. PubMed 23712209 DOI: 10.1038/nrurol.2013.111

146. Somford DM, Hamoen EH, Fütterer JJ, van Basten JP, Hulsbergen-van de Kaa CA, Vreuls W, et al. Including Barentsz JO. The predictive value of endorectal 3 Tesla multiparametric magnetic resonance imaging for extraprostatic extension in patients with low, intermediate and high risk prostate cancer. J Urol. 2013;190(5):1728-34. PubMed 23680307 DOI: 10.1016/j.juro.2013.05.021

147. Dickinson L, Ahmed HU, Allen C, Barentsz JO, Carey B, Futterer JJ, et al. Clinical applications of multiparametric MRI within the prostate cancer diagnostic pathway. Urol Oncol. 2013;31(3):281-4. PubMed 23627000 DOI: 10.1016/j.urolonc.2012.02.004

148. Hoeks CM, Vos EK, Bomers JG, Barentsz JO, Hulsbergen-van de Kaa CA, Scheenen TW. Diffusion-weighted magnetic resonance imaging in the prostate transition zone: histopathological validation using magnetic resonance-guided biopsy specimens. Invest Radiol. 2013;48(10):693-701. PubMed 23614975 DOI: 10.1097/RLI.0b013e31828eeaf9

149. Overduin CG, Fütterer JJ, Barentsz JO. MRI-guided biopsy for prostate cancer detection: a systematic review of current clinical results. Curr Urol Rep. 2013;14(3):209-13. PubMed 23568624 DOI: 10.1007/s11934-013-0323-z

150. Bomers JG, Yakar D, Overduin CG, Sedelaar JP, Vergunst H, Barentsz JO, et al. MR imaging-guided focal cryoablation in patients with recurrent prostate cancer. Radiology. 2013;268(2):451-60. PubMed 23525206 DOI: 10.1148/radiol.13121291

151. Fortuin AS, Barentsz JO. Comments on Ultrasmall superparamagnetic particles of iron oxide allow for the detection of metastases in normal sized pelvic lymph nodes of patients with bladder and/or prostate cancer, Triantafyllou et al., European Journal of Cancer, published online 22 October 2012. Eur J Cancer. 2013;49(7):1789-90. PubMed 23465494 DOI: 10.1016/j.ejca.2013.01.023

152. Nagel KN, Schouten MG, Hambrock T, Litjens GJ, Hoeks CM, ten Haken B, et al. Including Barentsz JO. Differentiation of prostatitis and prostate cancer by using diffusion-weighted MR imaging and MR-guided biopsy at 3 T. Radiology. 2013;267(1):164-72. PubMed 23329653 DOI: 10.1148/radiol.12111683

153. Somford DM, Hoeks CM, Hulsbergen-van de Kaa CA, Hambrock T, Fütterer JJ, Witjes JA, et al. Including Barentsz JO. Evaluation of diffusion-weighted MR imaging at inclusion in an active surveillance protocol for low-risk prostate cancer. Invest Radiol. 2013;48(3):152-7. PubMed 23328910 DOI: 10.1097/RLI.0b013e31827b711e

154. Hambrock T, Vos PC, Hulsbergen-van de Kaa CA, Barentsz JO, Huisman HJ. Prostate cancer: computer-aided diagnosis with multiparametric 3-T MR imaging--effect on observer performance. Radiology. 2013;266(2):521-30. PubMed 23204542 DOI: 10.1148/radiol.12111634

155. Meijer HJ, Fortuin AS, van Lin EN, Debats OA, Alfred Witjes J, Kaanders JH, et al. Including Barentsz JO. Geographical distribution of lymph node metastases on MR lymphography in prostate cancer patients. Radiother Oncol. 2013;106(1):59-63. PubMed 23199653 DOI: 10.1016/j.radonc.2012.10.021

156. Hoeks CM, Hambrock T, Yakar D, Hulsbergen-van de Kaa CA, Feuth T, Witjes JA, et al. Including Barentsz JO. Transition zone prostate cancer: detection and localization with 3-T multiparametric MR imaging. Radiology. 2013;266(1):207-17. PubMed 23143029 DOI: 10.1148/radiol.12120281

157. van de Ven WJ, Hulsbergen-van de Kaa CA, Hambrock T, Barentsz JO, Huisman HJ. Simulated required accuracy of image registration tools for targeting high-grade cancer components with prostate biopsies. Eur Radiol. 2013;23(5):1401-7. PubMed 23138386 DOI: 10.1007/s00330-012-2701-1

158. van Niekerk CG, Witjes JA, Barentsz JO, van der Laak JA, Hulsbergen-van de Kaa CA. Microvascularity in transition zone prostate tumors resembles normal prostatic tissue. Prostate. 2013;73(5):467-75. PubMed 22996830 DOI: 10.1002/pros.22588

159. Dickinson L, Ahmed HU, Allen C, Barentsz JO, Carey B, Futterer JJ, et al. Scoring systems used for the interpretation and reporting of multiparametric MRI for prostate cancer detection, localization, and characterization: could standardization lead to improved utilization of imaging within the diagnostic pathway? J Magn Reson Imaging. 2013;37(1):48-58. PubMed 22566285 DOI: 10.1002/jmri.23689

2012

160. Bomers JG, Sedelaar JP, Barentsz JO, Fütterer JJ. MRI-guided interventions for the treatment of prostate cancer. AJR Am J Roentgenol. 2012;199(4):714-20. PubMed 22997360 DOI: 10.2214/AJR.12.8725

161. Litjens GJ, Hambrock T, Hulsbergen-van de Kaa C, Barentsz JO, Huisman HJ. Interpatient variation in normal peripheral zone apparent diffusion coefficient: effect on the prediction of prostate cancer aggressiveness. Radiology. 2012;265(1):260-6. PubMed 22923722 DOI: 10.1148/radiol.12112374

162. Kobus T, Vos PC, Hambrock T, De Rooij M, Hulsbergen-Van de Kaa CA, Barentsz JO, et al. Prostate cancer aggressiveness: in vivo assessment of MR spectroscopy and diffusion-weighted imaging at 3 T. Radiology. 2012;265(2):457-67. PubMed 22843767 DOI: 10.1148/radiol.12111744

163. Stoutjesdijk MJ, Zijp M, Boetes C, Karssemeijer N, Barentsz JO, Huisman H. Computer aided analysis of breast MRI enhancement kinetics using mean shift clustering and multifeature iterative region of interest selection. J Magn Reson Imaging. 2012;36(5):1104-12. PubMed 22786883 DOI: 10.1002/jmri.23746

164. Fütterer JJ, Barentsz JO. MRI-guided and robotic-assisted prostate biopsy. Curr Opin Urol. 2012;22(4):316-9. PubMed 22617059 DOI: 10.1097/MOU.0b013e328354833c

165. Leach MO, Morgan B, Tofts PS, Buckley DL, Huang W, Horsfield MA, et al. Including Barentsz J. Imaging vascular function for early stage clinical trials using dynamic contrast-enhanced magnetic resonance imaging. Eur Radiol. 2012;22(7):1451-64. PubMed 22562143 DOI: 10.1007/s00330-012-2446-x

166. Meijer HJ, Debats OA, Roach M, Span PN, Witjes JA, Kaanders JH, et al. Including Barentsz JO. Magnetic resonance lymphography findings in patients with biochemical recurrence after prostatectomy and the relation with the Stephenson nomogram. Int J Radiat Oncol Biol Phys. 2012;84(5):1186-91. PubMed 22520482 DOI: 10.1016/j.ijrobp.2012.02.039

167. Smeenge M, Barentsz J, Cosgrove D, de la Rosette J, de Reijke T, Eggener S, et al. Role of transrectal ultrasonography (TRUS) in focal therapy of prostate cancer: report from a Consensus Panel. BJU Int. 2012;110(7):942-8. PubMed 22462566 DOI: 10.1111/j.1464-410X.2012.11072.x

168. Fortuin AS, Deserno WM, Meijer HJ, Jager GJ, Takahashi S, Debats OA, et al. Including Barentsz JO. Value of PET/CT and MR lymphography in treatment of prostate cancer patients with lymph node metastases. Int J Radiat Oncol Biol Phys. 2012;84(3):712-8. PubMed 22417806 DOI: 10.1016/j.ijrobp.2011.12.093

169. Vos PC, Barentsz JO, Karssemeijer N, Huisman HJ. Automatic computer-aided detection of prostate cancer based on multiparametric magnetic resonance image analysis. Phys Med Biol. 2012;57(6):1527-42. PubMed 22391091 DOI: 10.1088/0031-9155/57/6/1527

170. Hoeks CM, Schouten MG, Bomers JG, Hoogendoorn SP, Hulsbergen-van de Kaa CA, Hambrock T, et al. Including Barentsz JO. Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers. Eur Urol. 2012;62(5):902-9. PubMed 22325447 DOI: 10.1016/j.eururo.2012.01.047

171. Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G, et al. ESUR prostate MR guidelines 2012. Eur Radiol. 2012;22(4):746-57. PubMed 22322308 DOI: 10.1007/s00330-011-2377-y

172. Somford DM, Hambrock T, Hulsbergen-van de Kaa CA, Fütterer JJ, van Oort IM, van Basten JP, et al. Including Barentsz JO. Initial experience with identifying high-grade prostate cancer using diffusion-weighted MR imaging (DWI) in patients with a Gleason score ≤ 3 + 3 = 6 upon schematic TRUS-guided biopsy: a radical prostatectomy correlated series. Invest Radiol. 2012;47(3):153-8. PubMed 22293513 DOI: 10.1097/RLI.0b013e31823ea1f0

173. Marberger M, Barentsz J, Emberton M, Hugosson J, Loeb S, Klotz L, et al. Novel approaches to improve prostate cancer diagnosis and management in early-stage disease. BJU Int. 2012;109 Suppl 2:1-7. PubMed 22257098 DOI: 10.1111/j.1464-410X.2011.10870.x

174. Yakar D, Debats OA, Bomers JG, Schouten MG, Vos PC, van Lin E, et al. Including Barentsz JO. Predictive value of MRI in the localization, staging, volume estimation, assessment of aggressiveness, and guidance of radiotherapy and biopsies in prostate cancer. J Magn Reson Imaging. 2012;35(1):20-31. PubMed 22174000 DOI: 10.1002/jmri.22790

175. Fütterer JJ, Verma S, Hambrock T, Yakar D, Barentsz JO. High-risk prostate cancer: value of multi-modality 3T MRI-guided biopsies after previous negative biopsies. Abdom Imaging. 2012;37(5):892-6. PubMed 22038330 DOI: 10.1007/s00261-011-9818-6

176. Lagemaat MW, Zechmann CM, Fütterer JJ, Weiland E, Lu J, Villeirs GM, et al. Including Barentsz JO. Reproducibility of 3D 1H MR spectroscopic imaging of the prostate at 1.5T. J Magn Reson Imaging. 2012;35(1):166-73. PubMed 21960013 DOI: 10.1002/jmri.22827

177. Hambrock T, Hoeks C, Hulsbergen-van de Kaa C, Scheenen T, Fütterer J, Bouwense S, et al. Including Barentsz J. Prospective assessment of prostate cancer aggressiveness using 3-T diffusion-weighted magnetic resonance imaging-guided biopsies versus a systematic 10-core transrectal ultrasound prostate biopsy cohort. Eur Urol. 2012;61(1):177-84. PubMed 21924545 DOI: 10.1016/j.eururo.2011.08.042

178. Meeuwis C, Veltman J, van Hall HN, Mus RD, Boetes C, Barentsz JO, et al. MR-guided breast biopsy at 3T: diagnostic yield of large core needle biopsy compared with vacuum-assisted biopsy. Eur Radiol. 2012;22(2):341-9. PubMed 21915606 DOI: 10.1007/s00330-011-2272-6

179. Bittencourt LK, Barentsz JO, de Miranda LC, Gasparetto EL. Prostate MRI: diffusion-weighted imaging at 1.5T correlates better with prostatectomy Gleason Grades than TRUS-guided biopsies in peripheral zone tumours. Eur Radiol. 2012;22(2):468-75. PubMed 21913058 DOI: 10.1007/s00330-011-2269-1

180. Meijer HJ, van Lin EN, Debats OA, Witjes JA, Span PN, Kaanders JH, et al. Including Barentsz JO. High occurrence of aberrant lymph node spread on magnetic resonance lymphography in prostate cancer patients with a biochemical recurrence after radical prostatectomy. Int J Radiat Oncol Biol Phys. 2012;82(4):1405-10. PubMed 21640507 DOI: 10.1016/j.ijrobp.2011.04.054

181. Meijer HJ, Debats OA, Kunze-Busch M, van Kollenburg P, Leer JW, Witjes JA, et al. Including Barentsz JO. Magnetic resonance lymphography-guided selective high-dose lymph node irradiation in prostate cancer. Int J Radiat Oncol Biol Phys. 2012;82(1):175-83. PubMed 21075555 DOI: 10.1016/j.ijrobp.2010.09.023

2011

182. Debats OA, Litjens GJ, Barentsz JO, Karssemeijer N, Huisman HJ. Automated 3-dimensional segmentation of pelvic lymph nodes in magnetic resonance images. Med Phys. 2011;38(11):6178-87. PubMed 22047383 DOI: 10.1118/1.3654162

183. Hoeks CM, Barentsz JO, Hambrock T, Yakar D, Somford DM, Heijmink SW, et al. Prostate cancer: multiparametric MR imaging for detection, localization, and staging. Radiology. 2011;261(1):46-66. PubMed 21931141 DOI: 10.1148/radiol.11091822

184. Wensing BM, Deserno WM, de Bondt RB, Marres HA, Merkx MA, Barentsz JO, et al. Diagnostic value of magnetic resonance lymphography in preoperative staging of clinically negative necks in squamous cell carcinoma of the oral cavity: a pilot study. Oral Oncol. 2011;47(11):1079-84. PubMed 21856211 DOI: 10.1016/j.oraloncology.2011.07.020

185. Nakai G, Matsuki M, Harada T, Tanigawa N, Yamada T, Barentsz J, et al. Evaluation of axillary lymph nodes by diffusion-weighted MRI using ultrasmall superparamagnetic iron oxide in patients with breast cancer: initial clinical experience. J Magn Reson Imaging. 2011;34(3):557-62. PubMed 21761468 DOI: 10.1002/jmri.22651

186. Heijmink SW, Fütterer JJ, Strum SS, Oyen WJ, Frauscher F, Witjes JA, et al. Including Barentsz JO. State-of-the-art uroradiologic imaging in the diagnosis of prostate cancer. Acta Oncol. 2011;50 Suppl 1:25-38. PubMed 21604938 DOI: 10.3109/0284186X.2010.578369

187. Hambrock T, Somford DM, Huisman HJ, van Oort IM, Witjes JA, Hulsbergen-van de Kaa CA, et al. Including Barentsz JO. Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. Radiology. 2011;259(2):453-61. PubMed 21502392 DOI: 10.1148/radiol.11091409

188. Barentsz J, Dickinson L, Sciarra A. Re: Axel Heidenreich. Consensus criteria for the use of magnetic resonance imaging in the diagnosis and staging of prostate cancer: not ready for routine use. Eur Urol 2011;59:495-7. Eur Urol. 2011;60(1):e5-6. PubMed 21429656 DOI: 10.1016/j.eururo.2011.03.013

189. Kobus T, Hambrock T, Hulsbergen-van de Kaa CA, Wright AJ, Barentsz JO, Heerschap A, et al. In vivo assessment of prostate cancer aggressiveness using magnetic resonance spectroscopic imaging at 3 T with an endorectal coil. Eur Urol. 2011;60(5):1074-80. PubMed 21419565 DOI: 10.1016/j.eururo.2011.03.002

190. Yakar D, Schouten MG, Bosboom DG, Barentsz JO, Scheenen TW, Fütterer JJ. Feasibility of a pneumatically actuated MR-compatible robot for transrectal prostate biopsy guidance. Radiology. 2011;260(1):241-7. PubMed 21406625 DOI: 10.1148/radiol.11101106

191. Sciarra A, Barentsz J, Bjartell A, Eastham J, Hricak H, Panebianco V, et al. Advances in magnetic resonance imaging: how they are changing the management of prostate cancer. Eur Urol. 2011;59(6):962-77. PubMed 21367519 DOI: 10.1016/j.eururo.2011.02.034

192. Weidner AM, van Lin EN, Dinter DJ, Rozema T, Schoenberg SO, Wenz F, et al. Including Barentsz JO. Ferumoxtran-10 MR lymphography for target definition and follow-up in a patient undergoing image-guided, dose-escalated radiotherapy of lymph nodes upon PSA relapse. Strahlenther Onkol. 2011;187(3):206-12. PubMed 21347637 DOI: 10.1007/s00066-010-2195-1

193. Yakar D, Heijmink SW, Hulsbergen-van de Kaa CA, Huisman H, Barentsz JO, Fütterer JJ, et al. Initial results of 3-dimensional 1H-magnetic resonance spectroscopic imaging in the localization of prostate cancer at 3 Tesla: should we use an endorectal coil? Invest Radiol. 2011;46(5):301-6. PubMed 21217527 DOI: 10.1097/RLI.0b013e3182007503

194. Dickinson L, Ahmed HU, Allen C, Barentsz JO, Carey B, Futterer JJ, et al. Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol. 2011;59(4):477-94. PubMed 21195536 DOI: 10.1016/j.eururo.2010.12.009

195. Scheenen TW, Fütterer J, Weiland E, van Hecke P, Lemort M, Zechmann C, et al. Including Barentsz J. Discriminating cancer from noncancer tissue in the prostate by 3-dimensional proton magnetic resonance spectroscopic imaging: a prospective multicenter validation study. Invest Radiol. 2011;46(1):25-33. PubMed 21188832 DOI: 10.1097/rli.0b013e3181f54081

196. van Leeuwen PJ, Kölble K, Huland H, Hambrock T, Barentsz J, Schröder FH. Prostate cancer detection and dutasteride: utility and limitations of prostate-specific antigen in men with previous negative biopsies. Eur Urol. 2011;59(2):183-90. PubMed 21130560 DOI: 10.1016/j.eururo.2010.09.035

197. Deserno WM, Debats OA, Rozema T, Fortuin AS, Heesakkers RA, Hoogeveen Y, et al. Including Barentsz JO. Comparison of nodal risk formula and MR lymphography for predicting lymph node involvement in prostate cancer. Int J Radiat Oncol Biol Phys. 2011;81(1):8-15. PubMed 20800390 DOI: 10.1016/j.ijrobp.2010.05.043

198. van Niekerk CG, Hulsbergen-van de Kaa CA, Barentsz JO, Witjes JA, van der Laak JA. Quantitative analysis of lymph vessel characteristics in organ confined prostate cancer. Prostate. 2011;71(1):91-7. PubMed 20632318 DOI: 10.1002/pros.21225

199. Meeuwis C, Mann RM, Mus RD, Winkel A, Boetes C, Barentsz JO, et al. MRI-guided breast biopsy at 3T using a dedicated large core biopsy set: feasibility and initial results. Eur J Radiol. 2011;79(2):257-61. PubMed 20541338 DOI: 10.1016/j.ejrad.2010.05.001

2010

200. de la Rosette J, Ahmed H, Barentsz J, Johansen TB, Brausi M, Emberton M, et al. Focal therapy in prostate cancer-report from a consensus panel. J Endourol. 2010;24(5):775-80. PubMed 20477543 DOI: 10.1089/end.2009.0596

201. Broekhuis SR, Hendriks JC, Fütterer JJ, Vierhout ME, Barentsz JO, Kluivers KB. Perineal descent and patients' symptoms of anorectal dysfunction, pelvic organ prolapse, and urinary incontinence. Int Urogynecol J. 2010;21(6):721-9. PubMed 20135303 DOI: 10.1007/s00192-010-1099-z

202. Yakar D, Hambrock T, Huisman H, Hulsbergen-van de Kaa CA, van Lin E, Vergunst H, et al. Including Barentsz JO. Feasibility of 3T dynamic contrast-enhanced magnetic resonance-guided biopsy in localizing local recurrence of prostate cancer after external beam radiation therapy. Invest Radiol. 2010;45(3):121-5. PubMed 20065860 DOI: 10.1097/RLI.0b013e3181c7bcda

203. Hambrock T, Somford DM, Hoeks C, Bouwense SA, Huisman H, Yakar D, et al. Including Barentsz JO. Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. J Urol. 2010;183(2):520-7. PubMed 20006859 DOI: 10.1016/j.juro.2009.10.022

204. Mann RM, Loo CE, Wobbes T, Bult P, Barentsz JO, Gilhuijs KG, et al. The impact of preoperative breast MRI on the re-excision rate in invasive lobular carcinoma of the breast. Breast Cancer Res Treat. 2010;119(2):415-22. PubMed 19885731 DOI: 10.1007/s10549-009-0616-6

2009

205. Hoeks CM, Fütterer JJ, Somford DM, van Oort IM, Huisman H, Barentsz JO. [Multiparametric MRI for prostate cancer screening]. Ned Tijdschr Geneeskd. 2009;153:B487. PubMed 20003566

206. Truijers M, Fütterer JJ, Takahashi S, Heesakkers RA, Blankensteijn JD, Barentsz JO. In vivo imaging of the aneurysm wall with MRI and a macrophage-specific contrast agent. AJR Am J Roentgenol. 2009;193(5):W437-41. PubMed 19843724 DOI: 10.2214/AJR.09.2619

207. Hövels AM, Heesakkers RA, Adang EM, Barentsz JO, Jager GJ, Severens JL. Cost-effectiveness of MR lymphography for the detection of lymph node metastases in patients with prostate cancer. Radiology. 2009;252(3):729-36. PubMed 19717752 DOI: 10.1148/radiol.2531071360

208. Broekhuis SR, Fütterer JJ, Hendriks JC, Barentsz JO, Vierhout ME, Kluivers KB. Symptoms of pelvic floor dysfunction are poorly correlated with findings on clinical examination and dynamic MR imaging of the pelvic floor. Int Urogynecol J Pelvic Floor Dysfunct. 2009;20(10):1169-74. PubMed 19597719 DOI: 10.1007/s00192-009-0938-2

209. Fütterer JJ, Barentsz J, Heijmijnk ST. Imaging modalities for prostate cancer. Expert Rev Anticancer Ther. 2009;9(7):923-37. PubMed 19589032 DOI: 10.1586/era.09.63

210. Heesakkers RA, Jager GJ, Hövels AM, de Hoop B, van den Bosch HC, Raat F, et al. Including Barentsz JO. Prostate cancer: detection of lymph node metastases outside the routine surgical area with ferumoxtran-10-enhanced MR imaging. Radiology. 2009;251(2):408-14. PubMed 19401573 DOI: 10.1148/radiol.2512071018

211. Broekhuis SR, Fütterer JJ, Barentsz JO, Vierhout ME, Kluivers KB. A systematic review of clinical studies on dynamic magnetic resonance imaging of pelvic organ prolapse: the use of reference lines and anatomical landmarks. Int Urogynecol J Pelvic Floor Dysfunct. 2009;20(6):721-9. PubMed 19271092 DOI: 10.1007/s00192-009-0848-3

212. Broekhuis SR, Kluivers KB, Hendriks JC, Fütterer JJ, Barentsz JO, Vierhout ME. POP-Q, dynamic MR imaging, and perineal ultrasonography: do they agree in the quantification of female pelvic organ prolapse? Int Urogynecol J Pelvic Floor Dysfunct. 2009;20(5):541-9. PubMed 19221680 DOI: 10.1007/s00192-009-0821-1

213. Kinkel K, Forstner R, Danza FM, Oleaga L, Cunha TM, Bergman A, et al. Including Barentsz JO. Staging of endometrial cancer with MRI: guidelines of the European Society of Urogenital Imaging. Eur Radiol. 2009;19(7):1565-74. PubMed 19194709 DOI: 10.1007/s00330-009-1309-6

214. Desar IM, van Herpen CM, van Laarhoven HW, Barentsz JO, Oyen WJ, van der Graaf WT. Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy. Cancer Treat Rev. 2009;35(4):309-21. PubMed 19136215 DOI: 10.1016/j.ctrv.2008.12.001

215. Heijmink SW, Scheenen TW, van Lin EN, Visser AG, Kiemeney LA, Witjes JA, et al. Including Barentsz JO. Changes in prostate shape and volume and their implications for radiotherapy after introduction of endorectal balloon as determined by MRI at 3T. Int J Radiat Oncol Biol Phys. 2009;73(5):1446-53. PubMed 19036532 DOI: 10.1016/j.ijrobp.2008.06.1491

216. Broekhuis SR, Kluivers KB, Hendriks JC, Vierhout ME, Barentsz JO, Fütterer JJ. Dynamic magnetic resonance imaging: reliability of anatomical landmarks and reference lines used to assess pelvic organ prolapse. Int Urogynecol J Pelvic Floor Dysfunct. 2009;20(2):141-8. PubMed 19002366 DOI: 10.1007/s00192-008-0760-2

217. van Niekerk CG, van der Laak JA, Börger ME, Huisman HJ, Witjes JA, Barentsz JO, et al. Computerized whole slide quantification shows increased microvascular density in pT2 prostate cancer as compared to normal prostate tissue. Prostate. 2009;69(1):62-9. PubMed 18780292 DOI: 10.1002/pros.20855

2008

218. Yakar D, Hambrock T, Hoeks C, Barentsz JO, Fütterer JJ. Magnetic resonance-guided biopsy of the prostate: feasibility, technique, and clinical applications. Top Magn Reson Imaging. 2008;19(6):291-5. PubMed 19512851 DOI: 10.1097/RMR.0b013e3181aacdb0

219. Fütterer JJ, Barentsz JO, Heijmink SW. Value of 3-T magnetic resonance imaging in local staging of prostate cancer. Top Magn Reson Imaging. 2008;19(6):285-9. PubMed 19512850 DOI: 10.1097/RMR.0b013e3181aa688f

220. Somford DM, Fütterer JJ, Hambrock T, Barentsz JO. Diffusion and perfusion MR imaging of the prostate. Magn Reson Imaging Clin N Am. 2008;16(4):685-95, ix. PubMed 18926431 DOI: 10.1016/j.mric.2008.07.002

221. Hambrock T, Fütterer JJ, Huisman HJ, Hulsbergen-vandeKaa C, van Basten JP, van Oort I, et al. Including Barentsz JO. Thirty-two-channel coil 3T magnetic resonance-guided biopsies of prostate tumor suspicious regions identified on multimodality 3T magnetic resonance imaging: technique and feasibility. Invest Radiol. 2008;43(10):686-94. PubMed 18791410 DOI: 10.1097/RLI.0b013e31817d0506

222. Heesakkers RA, Hövels AM, Jager GJ, van den Bosch HC, Witjes JA, Raat HP, et al. Including Barentsz J. MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study. Lancet Oncol. 2008;9(9):850-6. PubMed 18708295 DOI: 10.1016/S1470-2045(08)70203-1

223. Pondman KM, Fütterer JJ, ten Haken B, Schultze Kool LJ, Witjes JA, Hambrock T, et al. Including Barentsz JO. MR-guided biopsy of the prostate: an overview of techniques and a systematic review. Eur Urol. 2008;54(3):517-27. PubMed 18571309 DOI: 10.1016/j.eururo.2008.06.001

224. Vos PC, Hambrock T, Hulsbergen-van de Kaa CA, Fütterer JJ, Barentsz JO, Huisman HJ. Computerized analysis of prostate lesions in the peripheral zone using dynamic contrast enhanced MRI. Med Phys. 2008;35(3):888-99. PubMed 18404925 DOI: 10.1118/1.2836419

225. Hövels AM, Heesakkers RA, Adang EM, Jager GJ, Strum S, Hoogeveen YL, et al. Including Barentsz JO. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol. 2008;63(4):387-95. PubMed 18325358 DOI: 10.1016/j.crad.2007.05.022

226. Veltman J, Stoutjesdijk M, Mann R, Huisman HJ, Barentsz JO, Blickman JG, et al. Contrast-enhanced magnetic resonance imaging of the breast: the value of pharmacokinetic parameters derived from fast dynamic imaging during initial enhancement in classifying lesions. Eur Radiol. 2008;18(6):1123-33. PubMed 18270714 DOI: 10.1007/s00330-008-0870-8

227. Fütterer JJ, Barentsz JO. Editorial comment on: role of dynamic contrast-enhanced magnetic resonance (MR) imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer. Eur Urol. 2008;54(3):599-600. PubMed 18226439 DOI: 10.1016/j.eururo.2007.12.036

228. Fuchsjäger M, Shukla-Dave A, Akin O, Barentsz J, Hricak H. Prostate cancer imaging. Acta Radiol. 2008;49(1):107-20. PubMed 18210320 DOI: 10.1080/02841850701545821

229. Fütterer JJ, Yakar D, Strijk SP, Barentsz JO. Preoperative 3T MR imaging of rectal cancer: local staging accuracy using a two-dimensional and three-dimensional T2-weighted turbo spin echo sequence. Eur J Radiol. 2008;65(1):66-71. PubMed 18164156 DOI: 10.1016/j.ejrad.2007.11.029

230. Mann RM, Veltman J, Barentsz JO, Wobbes T, Blickman JG, Boetes C. The value of MRI compared to mammography in the assessment of tumour extent in invasive lobular carcinoma of the breast. Eur J Surg Oncol. 2008;34(2):135-42. PubMed 17574805 DOI: 10.1016/j.ejso.2007.04.020

2007

231. Scheenen TW, Heijmink SW, Roell SA, Hulsbergen-Van de Kaa CA, Knipscheer BC, Witjes JA, et al. Including Barentsz JO. Three-dimensional proton MR spectroscopy of human prostate at 3 T without endorectal coil: feasibility. Radiology. 2007;245(2):507-16. PubMed 17848681 DOI: 10.1148/radiol.2451061444

232. Stoutjesdijk MJ, Veltman J, Huisman H, Karssemeijer N, Barentsz JO, Blickman JG, et al. Automated analysis of contrast enhancement in breast MRI lesions using mean shift clustering for ROI selection. J Magn Reson Imaging. 2007;26(3):606-14. PubMed 17729367 DOI: 10.1002/jmri.21026

233. Heijmink SW, Barentsz JO. Contrast-enhanced versus systematic transrectal ultrasound-guided prostate cancer detection: an overview of techniques and a systematic review. Eur J Radiol. 2007;63(3):310-6. PubMed 17719734 DOI: 10.1016/j.ejrad.2007.06.027

234. Barentsz JO, Fütterer JJ, Takahashi S. Use of ultrasmall superparamagnetic iron oxide in lymph node MR imaging in prostate cancer patients. Eur J Radiol. 2007;63(3):369-72. PubMed 17689215 DOI: 10.1016/j.ejrad.2007.06.025

235. Heijmink SW, Scheenen TW, Fütterer JJ, Klomp DW, Heesakkers RA, Hulsbergen-van de Kaa CA, et al. Including Barentsz JO. Prostate and lymph node proton magnetic resonance (MR) spectroscopic imaging with external array coils at 3 T to detect recurrent prostate cancer after radiation therapy. Invest Radiol. 2007;42(6):420-7. PubMed 17507814 DOI: 10.1097/01.rli.0000262759.46364.50

236. Heijmink SW, Fütterer JJ, Hambrock T, Takahashi S, Scheenen TW, Huisman HJ, et al. Including Barentsz JO. Prostate cancer: body-array versus endorectal coil MR imaging at 3 T--comparison of image quality, localization, and staging performance. Radiology. 2007;244(1):184-95. PubMed 17495178 DOI: 10.1148/radiol.2441060425

237. Fütterer JJ, Scheenen TW, Heijmink SW, Huisman HJ, Hulsbergen-Van de Kaa CA, Witjes JA, et al. Including Barentsz JO. Standardized threshold approach using three-dimensional proton magnetic resonance spectroscopic imaging in prostate cancer localization of the entire prostate. Invest Radiol. 2007;42(2):116-22. PubMed 17220729 DOI: 10.1097/01.rli.0000251541.03822.bb

238. Fütterer JJ, Engelbrecht MR, Jager GJ, Hartman RP, King BF, Hulsbergen-Van de Kaa CA, et al. Including Barentsz JO. Prostate cancer: comparison of local staging accuracy of pelvic phased-array coil alone versus integrated endorectal-pelvic phased-array coils. Local staging accuracy of prostate cancer using endorectal coil MR imaging. Eur Radiol. 2007;17(4):1055-65. PubMed 17024497 DOI: 10.1007/s00330-006-0418-8

239. van Laarhoven HW, Klomp DW, Rijpkema M, Kamm YL, Wagener DJ, Barentsz JO, et al. Prediction of chemotherapeutic response of colorectal liver metastases with dynamic gadolinium-DTPA-enhanced MRI and localized 19F MRS pharmacokinetic studies of 5-fluorouracil. NMR Biomed. 2007;20(2):128-40. PubMed 17006886 DOI: 10.1002/nbm.1098

240. Thomsen HS, Barentsz JO, Burcharth F, Chabanova E, Dekker HM, Moesgaard F, et al. Initial clinical experience with oral manganese (CMC-001) for liver MR imaging. Eur Radiol. 2007;17(1):273-8. PubMed 16763790 DOI: 10.1007/s00330-006-0336-9

2006

241. Fütterer JJ, Heijmink SW, Scheenen TW, Veltman J, Huisman HJ, Vos P, et al. Including Barentsz JO. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology. 2006;241(2):449-58. PubMed 16966484 DOI: 10.1148/radiol.2412051866

242. Barentsz J, Takahashi S, Oyen W, Mus R, De Mulder P, Reznek R, et al. Commonly used imaging techniques for diagnosis and staging. J Clin Oncol. 2006;24(20):3234-44. PubMed 16829647 DOI: 10.1200/JCO.2006.06.5946

243. Chabanova E, Logager V, Moller JM, Dekker H, Barentsz J, Thomsen HS. Imaging liver metastases with a new oral manganese-based contrast agent. Acad Radiol. 2006;13(7):827-32. PubMed 16777556 DOI: 10.1016/j.acra.2006.03.013

244. Heesakkers RA, Fütterer JJ, Hövels AM, van den Bosch HC, Scheenen TW, Hoogeveen YL, et al. Including Barentsz JO. Prostate cancer evaluated with ferumoxtran-10-enhanced T2*-weighted MR Imaging at 1.5 and 3.0 T: early experience. Radiology. 2006;239(2):481-7. PubMed 16641354 DOI: 10.1148/radiol.2392050411

245. van Lin EN, Fütterer JJ, Heijmink SW, van der Vight LP, Hoffmann AL, van Kollenburg P, et al. Including Barentsz JO. IMRT boost dose planning on dominant intraprostatic lesions: gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI. Int J Radiat Oncol Biol Phys. 2006;65(1):291-303. PubMed 16618584 DOI: 10.1016/j.ijrobp.2005.12.046

246. Goldfarb JW, Holland AE, Heijstraten FM, Skotnicki S, Barentsz JO. Cardiac-synchronized gadolinium-enhanced MR angiography: preliminary experience for the evaluation of the thoracic aorta. Magn Reson Imaging. 2006;24(3):241-8. PubMed 16563952 DOI: 10.1016/j.mri.2005.12.001

247. van Moerkerk H, Heijmink SW, Kaa CA, Barentsz JO, Witjes JA. Computerized three-dimensional localization of prostate cancer using contrast-enhanced power Doppler and clustering analysis. Eur Urol. 2006;50(4):762-8; discussion 768-9. PubMed 16527394 DOI: 10.1016/j.eururo.2006.02.028

248. Veltman J, Boetes C, van Die L, Bult P, Blickman JG, Barentsz JO. Mammographic detection and staging of invasive lobular carcinoma. Clin Imaging. 2006;30(2):94-8. PubMed 16500539 DOI: 10.1016/j.clinimag.2005.09.021

249. Schrier BP, Peters M, Barentsz JO, Witjes JA. Evaluation of chemotherapy with magnetic resonance imaging in patients with regionally metastatic or unresectable bladder cancer. Eur Urol. 2006;49(4):698-703. PubMed 16464531 DOI: 10.1016/j.eururo.2006.01.022

250. Heijmink SW, van Moerkerk H, Kiemeney LA, Witjes JA, Frauscher F, Barentsz JO. A comparison of the diagnostic performance of systematic versus ultrasound-guided biopsies of prostate cancer. Eur Radiol. 2006;16(4):927-38. PubMed 16391907 DOI: 10.1007/s00330-005-0035-y

251. Fütterer JJ, Heijmink SW, Scheenen TW, Jager GJ, Hulsbergen-Van de Kaa CA, Witjes JA, et al. Including Barentsz JO. Prostate cancer: local staging at 3-T endorectal MR imaging--early experience. Radiology. 2006;238(1):184-91. PubMed 16304091 DOI: 10.1148/radiol.2381041832

2005

252. de Vries IJ, Lesterhuis WJ, Barentsz JO, Verdijk P, van Krieken JH, Boerman OC, et al. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol. 2005;23(11):1407-13. PubMed 16258544 DOI: 10.1038/nbt1154

253. Fütterer JJ, Engelbrecht MR, Huisman HJ, Jager GJ, Hulsbergen-van De Kaa CA, Witjes JA, et al. Including Barentsz JO. Staging prostate cancer with dynamic contrast-enhanced endorectal MR imaging prior to radical prostatectomy: experienced versus less experienced readers. Radiology. 2005;237(2):541-9. PubMed 16244263 DOI: 10.1148/radiol.2372041724

254. Huisman HJ, Fütterer JJ, van Lin EN, Welmers A, Scheenen TW, van Dalen JA, et al. Including Barentsz JO. Prostate cancer: precision of integrating functional MR imaging with radiation therapy treatment by using fiducial gold markers. Radiology. 2005;236(1):311-7. PubMed 15983070 DOI: 10.1148/radiol.2361040560

255. Scheenen TW, Gambarota G, Weiland E, Klomp DW, Fütterer JJ, Barentsz JO, et al. Optimal timing for in vivo 1H-MR spectroscopic imaging of the human prostate at 3T. Magn Reson Med. 2005;53(6):1268-74. PubMed 15906304 DOI: 10.1002/mrm.20468

256. Veltman J, Boetes C, Wobbes T, Blickman JG, Barentsz JO. Magnetic resonance-guided biopsies and localizations of the breast: initial experiences using an open breast coil and compatible intervention device. Invest Radiol. 2005;40(6):379-84. PubMed 15905725 DOI: 10.1097/01.rli.0000163672.90247.70

257. Stoutjesdijk MJ, Fütterer JJ, Boetes C, van Die LE, Jager G, Barentsz JO. Variability in the description of morphologic and contrast enhancement characteristics of breast lesions on magnetic resonance imaging. Invest Radiol. 2005;40(6):355-62. PubMed 15905722 DOI: 10.1097/01.rli.0000163741.16718.3e

2004

258. Fütterer JJ, Scheenen TW, Huisman HJ, Klomp DW, van Dorsten FA, Hulsbergen-van de Kaa CA, et al. Including Barentsz JO. Initial experience of 3 tesla endorectal coil magnetic resonance imaging and 1H-spectroscopic imaging of the prostate. Invest Radiol. 2004;39(11):671-80. PubMed 15486528 DOI: 10.1097/00004424-200411000-00005

259. Deserno WM, Harisinghani MG, Taupitz M, Jager GJ, Witjes JA, Mulders PF, et al. Including Barentsz JO. Urinary bladder cancer: preoperative nodal staging with ferumoxtran-10-enhanced MR imaging. Radiology. 2004;233(2):449-56. PubMed 15375228 DOI: 10.1148/radiol.2332031111

260. van Dorsten FA, van der Graaf M, Engelbrecht MR, van Leenders GJ, Verhofstad A, Rijpkema M, et al. Including Barentsz JO. Combined quantitative dynamic contrast-enhanced MR imaging and (1)H MR spectroscopic imaging of human prostate cancer. J Magn Reson Imaging. 2004;20(2):279-87. PubMed 15269954 DOI: 10.1002/jmri.20113

261. Hövels AM, Heesakkers RA, Adang EM, Jager GJ, Barentsz JO. Cost-analysis of staging methods for lymph nodes in patients with prostate cancer: MRI with a lymph node-specific contrast agent compared to pelvic lymph node dissection or CT. Eur Radiol. 2004;14(9):1707-12. PubMed 15249979 DOI: 10.1007/s00330-004-2374-5

262. Scheenen TW, Klomp DW, Röll SA, Fütterer JJ, Barentsz JO, Heerschap A. Fast acquisition-weighted three-dimensional proton MR spectroscopic imaging of the human prostate. Magn Reson Med. 2004;52(1):80-8. PubMed 15236370 DOI: 10.1002/mrm.20103

263. Boetes C, Veltman J, van Die L, Bult P, Wobbes T, Barentsz JO. The role of MRI in invasive lobular carcinoma. Breast Cancer Res Treat. 2004;86(1):31-7. PubMed 15218359 DOI: 10.1023/B:BREA.0000032921.10481.dc

264. Vogel WV, Oyen WJ, Barentsz JO, Kaanders JH, Corstens FH. PET/CT: panacea, redundancy, or something in between? J Nucl Med. 2004;45 Suppl 1:15S-24S. PubMed 14736832

2003

265. Witjes JA, Vriesema JL, Brinkman K, Bootsma G, Barentsz JO. Mycotic aneurysm of the popliteal artery as a complication of intravesical BCG therapy for superficial bladder cancer. Case report and literature review. Urol Int. 2003;71(4):430-2. PubMed 14646447 DOI: 10.1159/000074100

266. Küsters B, de Waal RM, Wesseling P, Verrijp K, Maass C, Heerschap A, et al. Including Barentsz JO. Differential effects of vascular endothelial growth factor A isoforms in a mouse brain metastasis model of human melanoma. Cancer Res. 2003;63(17):5408-13. PubMed 14500375

267. Engelbrecht MR, Huisman HJ, Laheij RJ, Jager GJ, van Leenders GJ, Hulsbergen-Van De Kaa CA, et al. Including Barentsz JO. Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging. Radiology. 2003;229(1):248-54. PubMed 12944607 DOI: 10.1148/radiol.2291020200

268. van Laarhoven HW, Rijpkema M, Punt CJ, Ruers TJ, Hendriks JC, Barentsz JO, et al. Method for quantitation of dynamic MRI contrast agent uptake in colorectal liver metastases. J Magn Reson Imaging. 2003;18(3):315-20. PubMed 12938126 DOI: 10.1002/jmri.10370

269. Wikström J, Wasser MN, Pattynama PM, Bonomo L, Hamm B, Del Maschio A, et al. Including Barentsz JO. Gadobenate dimeglumine-enhanced magnetic resonance angiography of the pelvic arteries. Invest Radiol. 2003;38(8):504-15. PubMed 12874517 DOI: 10.1097/01.rli.0000074585.46615.2e

270. Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med. 2003;348(25):2491-9. PubMed 12815134 DOI: 10.1056/NEJMoa022749

271. Nollen GJ, van Schijndel KE, Timmermans J, Groenink M, Barentsz JO, van der Wall EE, et al. Magnetic resonance imaging of the main pulmonary artery: reliable assessment of dimensions in Marfan patients on a simple axial spin echo image. Int J Cardiovasc Imaging. 2003;19(2):141-7; discussion 149-50. PubMed 12749395 DOI: 10.1023/a:1022860919684

272. Leenders W, Küsters B, Pikkemaat J, Wesseling P, Ruiter D, Heerschap A, et al. Including Barentsz J. Vascular endothelial growth factor-A determines detectability of experimental melanoma brain metastasis in GD-DTPA-enhanced MRI. Int J Cancer. 2003;105(4):437-43. PubMed 12712432 DOI: 10.1002/ijc.11102

273. Nollen GJ, Meijboom LJ, Groenink M, Timmermans J, Barentsz JO, Merchant N, et al. Comparison of aortic elasticity in patients with the marfan syndrome with and without aortic root replacement. Am J Cardiol. 2003;91(5):637-40. PubMed 12615284 DOI: 10.1016/s0002-9149(02)03330-1

2002

274. Kroencke TJ, Wasser MN, Pattynama PM, Barentsz JO, Grabbe E, Marchal G, et al. Gadobenate dimeglumine-enhanced MR angiography of the abdominal aorta and renal arteries. AJR Am J Roentgenol. 2002;179(6):1573-82. PubMed 12438058 DOI: 10.2214/ajr.179.6.1791573

275. Engelbrecht MR, Jager GJ, Laheij RJ, Verbeek AL, van Lier HJ, Barentsz JO. Local staging of prostate cancer using magnetic resonance imaging: a meta-analysis. Eur Radiol. 2002;12(9):2294-302. PubMed 12195484 DOI: 10.1007/s00330-002-1389-z

276. Harisinghani MG, Barentsz JO, Hahn PF, Deserno W, de la Rosette J, Saini S, et al. MR lymphangiography for detection of minimal nodal disease in patients with prostate cancer. Acad Radiol. 2002;9 Suppl 2:S312-3. PubMed 12188258 DOI: 10.1016/s1076-6332(03)80213-1

277. Holland AE, Engelbrecht MR, Barentsz JO, Heijstraten FM, Goldfarb JW. The value of single-shot black-blood MR imaging for mapping of the coronary arteries: a comparison of four different orientations during breath-holding and free breathing. Magn Reson Imaging. 2002;20(3):261-9. PubMed 12117608 DOI: 10.1016/s0730-725x(02)00492-7

278. Nollen GJ, van Schijndel KE, Timmermans J, Groenink M, Barentsz JO, van der Wall EE, et al. Pulmonary artery root dilatation in Marfan syndrome: quantitative assessment of an unknown criterion. Heart. 2002;87(5):470-1. PubMed 11997425 DOI: 10.1136/heart.87.5.470

279. Cruz M, Tsuda K, Narumi Y, Kuroiwa Y, Nose T, Kojima Y, et al. Including Barentsz JO. Characterization of low-intensity lesions in the peripheral zone of prostate on pre-biopsy endorectal coil MR imaging. Eur Radiol. 2002;12(2):357-65. PubMed 11870434 DOI: 10.1007/s003300101044

2001

280. Stoutjesdijk MJ, Barentsz JO. Prophylactic mastectomy in carriers of BRCA mutations. N Engl J Med. 2001;345(20):1499; author reply 1499-500. PubMed 11794206

281. Stoutjesdijk MJ, Boetes C, Jager GJ, Beex L, Bult P, Hendriks JH, et al. Including Barentsz JO. Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer. J Natl Cancer Inst. 2001;93(14):1095-102. PubMed 11459871 DOI: 10.1093/jnci/93.14.1095

282. Huisman HJ, Engelbrecht MR, Barentsz JO. Accurate estimation of pharmacokinetic contrast-enhanced dynamic MRI parameters of the prostate. J Magn Reson Imaging. 2001;13(4):607-14. PubMed 11276106 DOI: 10.1002/jmri.1085

283. Boss EA, Massuger LF, Pop LA, Verhoef LC, Huisman HJ, Boonstra H, et al. Including Barentsz JO. Post-radiotherapy contrast enhancement changes in fast dynamic MRI of cervical carcinoma. J Magn Reson Imaging. 2001;13(4):600-6. PubMed 11276105 DOI: 10.1002/jmri.1084

2000

284. Barentsz JO, Jager GJ, Witjes JA. MR imaging of the urinary bladder. Magn Reson Imaging Clin N Am. 2000;8(4):853-67. PubMed 11149683

285. Engelbrecht MR, Barentsz JO, Jager GJ, van der Graaf M, Heerschap A, Sedelaar JP, et al. Prostate cancer staging using imaging. BJU Int. 2000;86 Suppl 1:123-34. PubMed 10961282 DOI: 10.1046/j.1464-410x.2000.00592.x

286. Holland AE, Barentsz JO, Heijstraten FM, Skotnicki S, Pruszczynski MS, Verheugt FW, et al. Images in cardiovascular medicine. Aortic dissection at the coronary artery sinus: magnetic resonance angiography findings. Circulation. 2000;102(5):597. PubMed 10920075 DOI: 10.1161/01.cir.102.5.597

287. Holland AE, Hendrick RE, Jin H, Russ PD, Barentsz JO, Holland R. Correlation of high-resolution breast MR imaging with histopathology; validation of a technique. J Magn Reson Imaging. 2000;11(6):601-6. PubMed 10862058 DOI: 10.1002/1522-2586(200006)11:6<601::aid-jmri5>3.0.co;2-g

288. Jager GJ, Severens JL, Thornbury JR, de La Rosette JJ, Ruijs SH, Barentsz JO. Prostate cancer staging: should MR imaging be used?--A decision analytic approach. Radiology. 2000;215(2):445-51. PubMed 10796923 DOI: 10.1148/radiology.215.2.r00ap09445

289. Holland AE, Barentsz JO, Skotnicki S, Ruijs SH, Goldfarb JW. Preoperative MRA assessment of the coronary arteries in an ascending aortic aneurysm. J Magn Reson Imaging. 2000;11(3):324-6. PubMed 10739564 DOI: 10.1002/(sici)1522-2586(200003)11:3<324::aid-jmri11>3.0.co;2-a

290. Korst MB, Joosten FB, Postma CT, Jager GJ, Krabbe JK, Barentsz JO. Accuracy of normal-dose contrast-enhanced MR angiography in assessing renal artery stenosis and accessory renal arteries. AJR Am J Roentgenol. 2000;174(3):629-34. PubMed 10701600 DOI: 10.2214/ajr.174.3.1740629

291. Boss EA, Barentsz JO, Massuger LF, Boonstra H. The role of MR imaging in invasive cervical carcinoma. Eur Radiol. 2000;10(2):256-70. PubMed 10663755 DOI: 10.1007/s003300050042

1999

292. Barentsz JO, Engelbrecht MR, Witjes JA, de la Rosette JJ, van der Graaf M. MR imaging of the male pelvis. Eur Radiol. 1999;9(9):1722-36. PubMed 10602944 DOI: 10.1007/s003300050916

293. van der Graaf M, van den Boogert HJ, Jager GJ, Barentsz JO, Heerschap A. Human prostate: multisection proton MR spectroscopic imaging with a single spin-echo sequence--preliminary experience. Radiology. 1999;213(3):919-25. PubMed 10580976 DOI: 10.1148/radiology.213.3.r99nv07919

294. Barentsz JO, Engelbrecht M, Jager GJ, Witjes JA, de LaRosette J, van Der Sanden BP, et al. Fast dynamic gadolinium-enhanced MR imaging of urinary bladder and prostate cancer. J Magn Reson Imaging. 1999;10(3):295-304. PubMed 10508289 DOI: 10.1002/(sici)1522-2586(199909)10:3<295::aid-jmri10>3.0.co;2-z

1998

295. Barentsz JO, Witjes JA. Magnetic resonance imaging of urinary bladder cancer. Curr Opin Urol. 1998;8(2):95-103. PubMed 17035849 DOI: 10.1097/00042307-199803000-00005

296. Engelbrecht MR, Hitge-Boetes C, Coolen J, Thijssen JM, Makkus AC, Bökkerink J, et al. Including Barentsz JO. Follow-up of Wilms' tumour during pre-operative chemotherapy by qualitative and quantitative sonography. Eur J Ultrasound. 1998;8(3):157-65. PubMed 9971895 DOI: 10.1016/s0929-8266(98)00070-6

297. Van Vierzen PB, Massuger LF, Ruys SH, Barentsz JO. Borderline ovarian malignancy: ultrasound and fast dynamic MR findings. Eur J Radiol. 1998;28(2):136-42. PubMed 9788017 DOI: 10.1016/s0720-048x(97)00122-8

298. Barentsz JO, Berger-Hartog O, Witjes JA, Hulsbergen-van der Kaa C, Oosterhof GO, VanderLaak JA, et al. Evaluation of chemotherapy in advanced urinary bladder cancer with fast dynamic contrast-enhanced MR imaging. Radiology. 1998;207(3):791-7. PubMed 9609906 DOI: 10.1148/radiology.207.3.9609906

299. Van Vierzen PB, Massuger LF, Ruys SH, Barentsz JO. Fast dynamic contrast enhanced MR imaging of cervical carcinoma. Clin Radiol. 1998;53(3):183-92. PubMed 9528868 DOI: 10.1016/s0009-9260(98)80098-6

1997

300. Franken DG, Barentsz JO, Heijstraten FM, Boers GH, Ruijs JH. Imaging of vascular pathology in hyperhomocysteinemic patients with digital subtraction angiography and magnetic resonance techniques. Eur Radiol. 1997;7(8):1335-40. PubMed 9377525 DOI: 10.1007/s003300050299

301. Boetes C, Strijk SP, Holland R, Barentsz JO, Van Der Sluis RF, Ruijs JH. False-negative MR imaging of malignant breast tumors. Eur Radiol. 1997;7(8):1231-4. PubMed 9377507 DOI: 10.1007/s003300050281

302. Barentsz JO, Witjes JA, Ruijs JH. What is new in bladder cancer imaging. Urol Clin North Am. 1997;24(3):583-602. PubMed 9275980 DOI: 10.1016/s0094-0143(05)70403-1

303. Barentsz JO. MR intervention in the pelvis: an overview and first experiences in MR-guided biopsy in nodal metastases in urinary bladder cancer. Abdom Imaging. 1997;22(5):524-30. PubMed 9233894 DOI: 10.1007/s002619900255

304. Heerschap A, Jager GJ, van der Graaf M, Barentsz JO, de la Rosette JJ, Oosterhof GO, et al. In vivo proton MR spectroscopy reveals altered metabolite content in malignant prostate tissue. Anticancer Res. 1997;17(3A):1455-60. PubMed 9179183

305. Jager GJ, Ruijter ET, van de Kaa CA, de la Rosette JJ, Oosterhof GO, Thornbury JR, et al. Including Barentsz JO. Dynamic TurboFLASH subtraction technique for contrast-enhanced MR imaging of the prostate: correlation with histopathologic results. Radiology. 1997;203(3):645-52. PubMed 9169683 DOI: 10.1148/radiology.203.3.9169683

306. Hendriks GW, Hasenbos MA, Gielen MJ, van Egmond J, Barentsz JO. Evaluation of thoracic epidural catheter position and migration using radio-opaque catheters. Anaesthesia. 1997;52(5):457-9. PubMed 9165966 DOI: 10.1111/j.1365-2044.1997.077-az0073.x

307. Huysmans D, Hermus A, Edelbroek M, Barentsz J, Corstens F, Kloppenborg P. Radioiodine for nontoxic multinodular goiter. Thyroid. 1997;7(2):235-9. PubMed 9133693 DOI: 10.1089/thy.1997.7.235

308. Heerschap A, Jager GJ, van der Graaf M, Barentsz JO, Ruijs SH. Proton MR spectroscopy of the normal human prostate with an endorectal coil and a double spin-echo pulse sequence. Magn Reson Med. 1997;37(2):204-13. PubMed 9001144 DOI: 10.1002/mrm.1910370212

1996

309. Jager GJ, Barentsz JO, Oosterhof GO, Witjes JA, Ruijs SJ. Pelvic adenopathy in prostatic and urinary bladder carcinoma: MR imaging with a three-dimensional TI-weighted magnetization-prepared-rapid gradient-echo sequence. AJR Am J Roentgenol. 1996;167(6):1503-7. PubMed 8956585 DOI: 10.2214/ajr.167.6.8956585

310. Barentsz JO, Jager GJ, van Vierzen PB, Witjes JA, Strijk SP, Peters H, et al. Staging urinary bladder cancer after transurethral biopsy: value of fast dynamic contrast-enhanced MR imaging. Radiology. 1996;201(1):185-93. PubMed 8816542 DOI: 10.1148/radiology.201.1.8816542

311. Barentsz JO, Jager GJ, Witjes JA, Ruijs JH. Primary staging of urinary bladder carcinoma: the role of MRI and a comparison with CT. Eur Radiol. 1996;6(2):129-33. PubMed 8797968 DOI: 10.1007/BF00181125

312. Jager GJ, Ruijter ET, van de Kaa CA, de la Rosette JJ, Oosterhof GO, Thornbury JR, et al. Including Barentsz JO. Local staging of prostate cancer with endorectal MR imaging: correlation with histopathology. AJR Am J Roentgenol. 1996;166(4):845-52. PubMed 8610561 DOI: 10.2214/ajr.166.4.8610561

1995

313. Barentsz J. MR in the evaluation of gynecologic tumor. J Belge Radiol. 1995;78(5):305-7. PubMed 8550398

314. Barentsz JO, Jager G, Mugler JP, Oosterhof G, Peters H, van Erning LT, et al. Staging urinary bladder cancer: value of T1-weighted three-dimensional magnetization prepared-rapid gradient-echo and two-dimensional spin-echo sequences. AJR Am J Roentgenol. 1995;164(1):109-15. PubMed 7998522 DOI: 10.2214/ajr.164.1.7998522

315. Boetes C, Mus RD, Holland R, Barentsz JO, Strijk SP, Wobbes T, et al. Breast tumors: comparative accuracy of MR imaging relative to mammography and US for demonstrating extent. Radiology. 1995;197(3):743-7. PubMed 7480749 DOI: 10.1148/radiology.197.3.7480749

1994

316. Morshuis W, Folgering H, Barentsz J, van Lier H, Lacquet L. Pulmonary function before surgery for pectus excavatum and at long-term follow-up. Chest. 1994;105(6):1646-52. PubMed 8205855 DOI: 10.1378/chest.105.6.1646

317. Morshuis WJ, Folgering HT, Barentsz JO, Cox AL, van Lier HJ, Lacquet LK. Exercise cardiorespiratory function before and one year after operation for pectus excavatum. J Thorac Cardiovasc Surg. 1994;107(6):1403-9. PubMed 8196380

318. Jager GJ, Barentsz JO, de la Rosette JJ, Rosenbusch G. Preliminary results of endorectal surface coil magnetic resonance imaging for local staging of prostate cancer. Radiologe. 1994;34(3):129-33. PubMed 8177947

319. Sallevelt PE, Barentsz JO, Ruijs SJ, Heijstraten FM, Buskens FG, Strijk SP. Role of MR imaging in the preoperative evaluation of atherosclerotic abdominal aortic aneurysms. Radiographics. 1994;14(1):87-98; discussion 99. PubMed 8128068 DOI: 10.1148/radiographics.14.1.8128068

320. Mulder HJ, Kaan GL, Nijveld A, van Oort A, Barentsz J, Lacquet LK. Coarctation developing after arterial switch repair for transposition of the great arteries. Ann Thorac Surg. 1994;58(1):227-9. PubMed 8037531 DOI: 10.1016/0003-4975(94)91107-x

321. Huysmans DA, de Haas MM, van den Broek WJ, Hermus AR, Barentsz JO, Corstens FH, et al. Magnetic resonance imaging for volume estimation of large multinodular goitres: a comparison with scintigraphy. Br J Radiol. 1994;67(798):519-23. PubMed 8032803 DOI: 10.1259/0007-1285-67-798-519

322. Boetes C, Barentsz JO, Mus RD, van der Sluis RF, van Erning LJ, Hendriks JH, et al. MR characterization of suspicious breast lesions with a gadolinium-enhanced TurboFLASH subtraction technique. Radiology. 1994;193(3):777-81. PubMed 7972823 DOI: 10.1148/radiology.193.3.7972823

323. Huysmans DA, Hermus AR, Corstens FH, Barentsz JO, Kloppenborg PW. Large, compressive goiters treated with radioiodine. Ann Intern Med. 1994;121(10):757-62. PubMed 7944053 DOI: 10.7326/0003-4819-121-10-199411150-00005

1993

324. Barentsz JO, Ruijs SH, Strijk SP. The role of MR imaging in carcinoma of the urinary bladder. AJR Am J Roentgenol. 1993;160(5):937-47. PubMed 8470608 DOI: 10.2214/ajr.160.5.8470608

325. Barentsz JO, Ruijs SH, van Erning LJ. Magnetic resonance imaging of urinary bladder cancer: an overview and new developments. Magn Reson Q. 1993;9(4):235-58. PubMed 8274374

1992

326. Barentsz JO. MRI of the abdomen and pelvis: an update in The Netherlands. Eur J Radiol. 1992;14(2):110-6. PubMed 1563411 DOI: 10.1016/0720-048x(92)90223-v

327. Bánki JH, Meiners LC, Barentsz JO, Witkamp TD. Detection of aortic dissection by magnetic resonance imaging in adults with Marfan's syndrome. Int J Card Imaging. 1992;8(4):249-54. PubMed 1464724 DOI: 10.1007/BF01146023

1991

328. Otten HJ, Barentsz JO, Cox AL, Lacquet LK. [Hemoptysis caused by a retained piece of chest drain]. Ned Tijdschr Geneeskd. 1991;135(21):947-50. PubMed 2052112

329. Morshuis WJ, Tanke RB, van de Wal HJ, Barentsz JO, Lacquet LK. [Purulent pericarditis in children. A continuously life-threatening disease]. Tijdschr Kindergeneeskd. 1991;59(1):36-9. PubMed 2031247

330. Witjes JA, De Vries JD, Schaafsma HE, Bogman MJ, Barentsz JO, Corten RL. Extramedullary plasmacytoma of the urethra: a case report. J Urol. 1991;145(4):826-8. PubMed 2005709 DOI: 10.1016/s0022-5347(17)38464-1

331. Postma CT, van Oijen AH, Barentsz JO, de Boo T, Hoefnagels WH, Corstens FH, et al. The value of tests predicting renovascular hypertension in patients with renal artery stenosis treated by angioplasty. Arch Intern Med. 1991;151(8):1531-5. PubMed 1831342

1990

332. Morshuis WJ, Cox AL, Lacquet LK, Mravunac M, Barentsz JO. Primary malignant fibrous histiocytoma of the mediastinum. Thorax. 1990;45(2):154-5. PubMed 2156345 DOI: 10.1136/thx.45.2.154

1989

333. Postma CT, Hoefnagels WH, Barentsz JO, de Boo T, Thien T. Occlusion of unilateral stenosed renal arteries--relation to medical treatment. J Hum Hypertens. 1989;3(3):185-90. PubMed 2769675

334. Sieswerda C, Skotnicki SH, Barentsz JO, Heystraten FM. Anastomotic aneurysms--an underdiagnosed complication after aorto-iliac reconstructions. Eur J Vasc Surg. 1989;3(3):233-8. PubMed 2744154 DOI: 10.1016/s0950-821x(89)80088-x

335. Van Son JA, Aengevaeren WR, Skotnicki SH, Barentsz JO, van de Wal HJ, Buskens FG. Diagnosis and management of the coronary-subclavian steal syndrome. Eur J Cardiothorac Surg. 1989;3(6):565-7. PubMed 2699811 DOI: 10.1016/1010-7940(89)90121-8

336. van Son JA, Morshuis WJ, Pijls NH, Barentsz JO, Buskens FG. [The diagnosis and treatment of cardiovascular disorders in Marfan syndrome]. Ned Tijdschr Geneeskd. 1989;133(33):1633-8. PubMed 2677779

1988

337. Barentsz JO, Lemmens JA, Ruijs SH, Boskamp EB, Hendrikx AJ, Karthaus HF, et al. Carcinoma of the urinary bladder: MR imaging with a double surface coil. AJR Am J Roentgenol. 1988;151(1):107-12. PubMed 3259791 DOI: 10.2214/ajr.151.1.107

338. de Waal Malefijt J, Slooff TJ, Huiskes R, de Laat EA, Barentsz JO. Vascular changes following hip arthroplasty. The femur in goats studied with and without cementation. Acta Orthop Scand. 1988;59(6):643-9. PubMed 3213450 DOI: 10.3109/17453678809149416

1987

339. Barentsz JO, Ruijs JH, Karthaus HF, van Daal WA, Debruyne FM, Rosenbusch G. [Potential of magnetic resonance tomography in malignant tumors of the urinary bladder]. Ned Tijdschr Geneeskd. 1987;131(48):2190-4. PubMed 3683664

340. Barentsz JO, Ruijs JH, Heystraten FM, Buskens F. Magnetic resonance imaging of the dissected thoracic aorta. Br J Radiol. 1987;60(713):499-502. PubMed 3580761 DOI: 10.1259/0007-1285-60-713-499

1986

341. Barentsz JO, Rosenbusch GR, Strijk SP, Yap SH. Radiologic examination in gastric cancer. A retrospective study of 188 patients. Acta Radiol Diagn (Stockh). 1986;27(5):547-52. PubMed 3799226 DOI: 10.1177/028418518602700511

342. Barentsz JO, Lemmens JA, Slooff TJ. The use of subtraction arthrography in total hip prosthesis. Acta Orthop Belg. 1986;52(3):274-5. PubMed 3538758

343. Barentsz JO, Lemmens JA, Boskamp EB, Rosenbusch G, Ruijs JH. Improved MR imaging of the bladder by using a new surface coil. Rofo. 1986;145(3):351-3. PubMed 3020646 DOI: 10.1055/s-2008-1048950

344. Barentsz JO, Lemmens JM, Slooff TJ. The use of subtraction arthrography in total hip arthroplasties. Rofo. 1986;144(4):440-6. PubMed 3008258 DOI: 10.1055/s-2008-1048819

1979

345. Barentsz JO, Muizebelt F, van der Schee AC, Toonen-van Beek AA. [A retrospective study of carcinoma of the uterine cervix and the value of cytological cervix studies in healthy women]. Ned Tijdschr Geneeskd. 1979;123(45):1932-6. PubMed 514382

Sources and editorial notes

Originally prepared 27 October 2026 from the supplied CV, the June 2025 website CV, professional profiles and PubMed metadata. Updated 9 November 2026 with the ESUR honorary membership and three completed doctorates confirmed by Professor Barentsz. Google Scholar and Scopus metrics were rechecked directly on the public author profiles on 9 November 2026. The PubMed bibliography retains its 27 October 2026 retrieval date.

Website CV June 2025

Google Scholar author profile and current citation metrics

Scopus author profile

PubMed author search

Academia Europaea profile

Radboudumc retirement announcement 24 November 2022

ORCID identity record

Editorial corrections include removal of duplicate CV sections, raw ORCID markup and conflicting legacy citation counts; use of 2022 for emeritus status; and separation of established clinical contributions from experimental research interests. Broad numerical claims about worldwide reductions in biopsies or overtreatment were omitted because they cannot be attributed precisely to an individual’s work from these sources.

The bibliography covers PubMed-indexed output, including publications from 2025 and 2026; rejected or unaccepted submissions supplied elsewhere in this conversation are not represented as published papers. Historical funding, book-chapter details and doctoral-supervision entries remain attributed to the supplied CV.